 
Official Title:  A Phase [ADDRESS_737852] Progressed Following  Platinum -Based 
Chemotherapy (POD1UM -202)  
NCT Number:  NCT0 3597295 
 
Document  Date :  
Clinical Study Protocol  Version 4 : [ADDRESS_737853] Progressed Following 
Platinum-Based Chemotherapy (POD1UM-202)  
 
 
Product:  INCMGA [ZIP_CODE]  
IND Number:  139,[ADDRESS_737854] Number:  2018 -002070 -51 
Phase of Study : 2 
Sponsor:  Incyte Corporation  
1801 Augustine Cut -Off 
Wilmington, DE [ZIP_CODE]  
Original  Protocol  (Version 0) : 12 JUN  2018  
Amendment (Version) 1:  06 AUG  2018  
Amendment (Version) 2:  [ADDRESS_737855] 2018  
Amendment (Version) 2 -NL: 26 NOV 2018  
Amendment (Version) 3:  21 MAR 2019  
Amendment (Version) 4:  [ADDRESS_737856] their origin in the Declaration of 
Helsinki and conducted in adherence to the study Protoc ol, applicable Good Clinical Practices, and applicable laws 
and country-specific regulations in which the study is being conducted.   The research in the Netherlands is carried 
out in accordance with the Declaration of Helsinki (Brazil, 2013) and the WMO (Medical Research Involving 
Human Subjects Act). 
The information in this document is confidential.  No part of this information may be duplicated, referenced, or 
transmitted in any form or by [CONTACT_61076] (electronic, mechanical, photocopy, recording, or otherwise) without prior 
written consent.  
Incyte Corporation Page 2 of 84 
Protocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL INVESTIGATOR'S AGREEMENT 
I have read the INCMGA 0012-202 Protocol Amendment 4 (Version 4 dated 08 JUL 2019) and 
a
gree to conduct the study as outlined.  I agree to maintain the confidentiality of all information 
received or developed in connection with this Protocol. 
 
 
   
(Printed Name [CONTACT_7919])    
   
   
(Signature [CONTACT_7919])   (Date)  
Incyte Corporation Page [ADDRESS_737857] OF ABBREVIATIONS ..........................................................................................................8 
1. P ROTOCOL SUMMARY..........................................................................................11  
2. I NTRODUCTION ......................................................................................................19  
2.1. B ackground .................................................................................................................19  
2.1.1.  INCMGA00012 ..........................................................................................................19  
2.2. Rationale for Study Design .........................................................................................20  
2.3. R ationale for Fixed Doses of INCMGA00012 ...........................................................21  
2.4. B enefit/Risk Assessment ............................................................................................22  
3. O BJECTIVES AND ENDPOINTS ............................................................................23  
4. S TUDY DESIGN .......................................................................................................24  
4.1. O verall Design ............................................................................................................24  
 25 
4.2. O verall Study Duration ...............................................................................................25  
4.3. S tudy Termination ......................................................................................................26  
4.3.1.  Data Monitoring Committee .......................................................................................26  
5. S TUDY POPULATION .............................................................................................27  
5.1. I nclusion Criteria ........................................................................................................27  
5.2. E xclusion Criteria .......................................................................................................28  
5.3. L ifestyle Considerations .............................................................................................30  
5.4. S creen Failures............................................................................................................30  
5.5. R eplacement of Participants .......................................................................................30  
6. S TUDY TREATMENT ..............................................................................................31  
6.1. S tudy Treatments Administered .................................................................................31  
6.2. Preparation, Handling, and Accountability.................................................................31  
6.3. Measures to Minimize Bias:  Randomization and Blinding .......................................32  
6.4. Study Treatment Compliance .....................................................................................32  
6.5. D ose Modifications .....................................................................................................32  
6.5.1.  Procedures for Participants Exhibiting Immune-Related Adverse Events .................34  
[IP_ADDRESS].  I
mmune-Mediated Pneumonitis..................................................................................34  
[IP_ADDRESS].  Immune-Mediated Colitis ...........................................................................................34  
[IP_ADDRESS].  Immune-Mediated Hepatitis .......................................................................................35  

Incyte Corporation Page 4 of 84 
Protocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL [IP_ADDRESS].  Immune-Mediated Endocrinopathies..........................................................................36  
[IP_ADDRESS].  Immune-Mediated Nephritis and Renal Dysfunction .................................................37  
[IP_ADDRESS]. I mmune-Mediated Skin Reactions..............................................................................37  
[IP_ADDRESS].  Immune-Mediated Myocarditis ..................................................................................37  
6.5.2.  Permanent Discontinuation of Study Drug Due to Toxicity.......................................38  
6.6. C oncomitant Medications and Procedures .................................................................38  
6.6.1.  Permitted Medications and Procedures.......................................................................39  
6.6.2.  Prohibited Medications and Procedures .....................................................................39  
6.7. T reatment After the End of the Study.........................................................................39  
7. D ISCONTINUATION OF STUDY TREATMENT AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL ..................................................................[ADDRESS_737858] to Follow- Up.......................................................................................................42  
8. S TUDY ASSESSMENTS AND PROCEDURES......................................................43  
8.1. A dministrative and General Procedures .....................................................................43  
8.1.1.  Informed Consent Process ..........................................................................................43  
8.1.2.  Screening Procedures..................................................................................................44  
8.1.3.  Interactive Response Technology Procedure..............................................................44  
8.1.4.  Distribution of Reminder Cards..................................................................................44  
8.1.5.  Demography and Medical History..............................................................................44  
[IP_ADDRESS].  Demographics and General Medical History..............................................................44  
[IP_ADDRESS].  Disease Characteristics and Treatment History ..........................................................44  
8.2. Efficacy Assessments .................................................................................................45  
8.2.1.  Tumor Imaging ...........................................................................................................45  
 46 
8.2.3.  Health Economics .......................................................................................................46  
 46 
 46 
 46 
 47 

Incyte Corporation Page 5 of 84 
Protocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 8.3. S afety Assessments .....................................................................................................47  
8.3.1.  Adverse Events ...........................................................................................................47  
8.3.2.  Physical Examinations ................................................................................................48  
8.3.3.  Vital Signs...................................................................................................................48  
8.3.4.  ECOG Performance Status .........................................................................................48  
8.3.5.  Electrocardiograms .....................................................................................................49  
8.3.6.  Laboratory Assessments .............................................................................................49  
[IP_ADDRESS].  Pregnancy Testing.......................................................................................................50  
8.4. Pharmacokinetic Assessments ....................................................................................52  
8.5. P harmacodynamic  Assessments ....................................................52  
8.5.1.  Description of Analyses ..............................................................................................52  
8.5.2.  Tissue Biopsies ...........................................................................................................52  
8.5.3.  Blood Sample Collection ............................................................................................53  
8.6. U nscheduled Visits .....................................................................................................53  
8.7. E nd of Treatment and/or Early Termination...............................................................[ADDRESS_737859]-Treatment Disease Foll ow-Up ............................................................................54  
8.8.3.  Survival Follow- Up ....................................................................................................54  
9. A DVERSE EVENTS:  DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING ......................55  
9.1. Definition of Adverse Event .......................................................................................55  
9.2. D efinition of Serious Adverse Event ..........................................................................56  
9.3. R ecording and Follow-Up of Adverse Events and/or Serious Adverse Events .........[ADDRESS_737860] Complaints.....................................................................................................61  
10. S TATISTICS ..............................................................................................................62  
10.1.  Sample Size Determination ........................................................................................62  
10.2.  Populations for Analysis .............................................................................................62  

Incyte Corporation Page 6 of 84 
Protocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 10.3.  Level of Significance ..................................................................................................62  
10.4.  Statistical Analyses .....................................................................................................62  
10.4.1.  Primary Analysis.........................................................................................................63  
[IP_ADDRESS].  Overall Response Rate ................................................................................................63  
[IP_ADDRESS].  Handling of Missing Data in Primary Analysis ..........................................................63  
10.4.2.  Secondary Analysis.....................................................................................................63  
[IP_ADDRESS].  Duration of Response..................................................................................................63  
[IP_ADDRESS].  Disease Control Rate ..................................................................................................63  
[IP_ADDRESS].  Progression-Free Survival...........................................................................................63  
[IP_ADDRESS].  Overall Survival ..........................................................................................................63  
10.4.3.  Safety Analyses...........................................................................................................64  
[IP_ADDRESS].  Adverse Events ...........................................................................................................64  
[IP_ADDRESS].  Adverse Events of Special Interest .............................................................................64  
[IP_ADDRESS].  Clinical Laboratory Tests............................................................................................64  
[IP_ADDRESS].  Vital Signs...................................................................................................................64  
[IP_ADDRESS].  Electrocardiograms .....................................................................................................64  
[IP_ADDRESS].  Dose Intensity .............................................................................................................[ADDRESS_737861] OF TABLES 
Table 1:  P rimary Objective and Endpoint.................................................................................11  
Table 2:  K ey Study Design Elements .......................................................................................11  
Table 3:  S chedule of Activities .................................................................................................13  
Table 4:  P harmacokinetic  Sample Collections (  
).....................................................................16  
Table 5:   
.
17 
Table 6:  O bjectives and Endpoints ...........................................................................................23  
Table 7:  E xclusionary Laboratory Values ................................................................................29  
Table 8:  S tudy Drug Information ..............................................................................................31  
Table 9:  G uidelines for Management of Suspected Infusion Reactions ...................................33  
Table 10:  R ecommended Approach to Handling Pneumonitis...................................................34  
Table 11:  R ecommended Approach for Handling Enterocolitis/Diarrhea..................................35  
Table 12:  R ecommended Approach for Handling Hepatitis.......................................................35  
Table 13:  R ecommended Approach for Handling Hypophysitis ................................................36  
Table 14: Recommended Approach for Handling Thyroid Disorders........................................36  
Table 15:  R ecommended Approach for Handling New Onset Diabetes Mellitus ......................36  
Table 16:  R ecommended Approach for Handling Nephritis and Renal Dysfunction ................37  
Table 17: Recommended Approach for Handling Skin Reactions .............................................37  
Table 18:  R ecommended Approach for Handling Myocarditis ..................................................38  
Table 19:  E COG Performance Status .........................................................................................48  
Table 20:  R equired Laboratory Analytes ....................................................................................51  
Table 21:  P opulations for Analysis .............................................................................................[ADDRESS_737862]  aspartate aminotransferase  
AUC 0-∞ area under the single -dose plasma or serum concentration -time curve 
extrapolated to infinity  
AUC 0-t area under the plasma or serum concentration -time curve from time = [ADDRESS_737863] measurable concentration at time =  t 
BCG  Bacillus Calmette –Guérin  
CFR Code of Federal Regulations  
CI confidence interval  
Cmax maximum observed plasma or serum concentration  
Cmin  minimum observed plasma or serum concentration over the dose interval  
Cmin,ss Cmin at steady state  
CNS  central nervous system  
CR complete response  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTFG  Clinical Trial Facilitation Group  
DCR  disease control rate  
DMC  Data Monitoring Committee  
DNA  deoxyribonucleic acid  
DOR  duration of response  
EBV  Epstein –Barr V irus 
ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture  
  
 
EOT  end of trea tment  
  
FAS full analysis set  
FDA  Food and Drug Administration  

Incyte Corporation Page [ADDRESS_737864] of 1996  
HIV human immunodeficiency virus  
HPV  human papi[INVESTIGATOR_561505]'s Brochure  
ICF informed consent form  
ICH Internatio nal Council on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
ICR Independent Central Radiographic Review  
IEC independent ethics committee  
IgG immunoglobulin G  
IgG4  immunoglobulin G4  
IgM immunoglobulin M  
IHC immunohistochemistry  
INR international normalized ratio  
irAE immune -related adverse event  
IRB institutional review board  
  
IRT interactive response technology  
IV intravenous  
LDL  low-density l ipoprotein  
MedDRA  Medical Dictionary for Regulatory Activities  
MTD  maximum tolerated dose  
NCI National Cancer Institute  
NSAID  nonsteroidal anti -inflammatory drug  
NSCLC  non–small cell lung cancer  
ORR  overall response rate  
OS overall survival  
PD progressive disease  
PD-[ADDRESS_737865] operating procedure  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
t½ apparent terminal -phase disposition half -life 
T3/FT3  triiodothyronine  
T4 thyroxine  
TEAE  treatment -emergent adverse event  
Tmax time to maximum concentration  
TSH  thyroid -stimulating hormone  
ULN  upper limit of normal  
WBC  white blood cell  
WMO  World Medical Association  

Incyte Corporation Page 11 of 84 
P
rotocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 1. PROTOCOL SUMMARY 
Protocol Title:   A P hase [ADDRESS_737866] Progressed Following Platinum-Based Chemotherapy 
(POD1UM-202) 
Protocol Number:   INCMGA 0012-202 
O
bjectives and Endpoints: 
Table 1 presents the primary objective and endpoint. 
T
able 1 : Primary Objective and Endpoint 
Objective  Endpoint  
Primary  
To assess efficacy of INCMGA00012 in terms of 
the ORR in participant s with locally advanced or 
metastatic SCAC who have progressed after 
platinum -based chemotherapy . ORR, defined as the percentage of participants 
having a CR or PR, according to RECIST v1.1 as 
determined by [CONTACT_89169] . 
Overall Design: 
Table 2 presents the key study design elements.  Further study details are presented after the 
t
able. 
Table 2 : Key Study Design Elements 
Study Phase  Phase [ADDRESS_737867] progressed after platinum -based chemotherapy . 
Number of 
Participants  Approximately  81 participants will be enrolled.  
Study Design  This is an open -label, single -group, multicenter, Phase 2 study . 
Estimated Duration 
of Study  
Participation  The study consists of 3 periods:  screening, s tudy drug treatment, and follow -up.  
Participants have up  to [ADDRESS_737868]  to follow -up, or premature 
discont inuation for any other reason.  
Independent Central 
Radiographic 
Review  Imaging w ill undergo independent central radiographic review in support of 
efficacy endpoints.  
Data Monitoring 
Committee (DMC)  Yes (external)  
Incyte Corporation Page 12 of 84 
P
rotocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Treatment Groups and Duration: 
All participants will receive INCMGA00012 at the recommended Phase 2 dose of 500 mg IV 
Q4W.  Treatment will be administered by [CONTACT_12781] 60 minutes on Day 1 of each 28-day 
c
ycle.  Subsequent treatment cycles should be delayed (for up to 12 weeks, Section 6.5)  until the 
following criteria are met:  
 Hemoglobin ≥ 8 gm/dL.  
 A
NC ≥ 1.0 × 109/L. 
 Platelet count ≥ 75 × 109/L. 
 A
LT/AST/bilirubin ≤ Grade 2. 
 R
esolution of all immune-related toxicity to ≤ Grade 1 (with the exception of 
endocrinopathy that is controlled on hormonal replacement), other than unacceptable 
toxicity per Section 6.5.2 . 
 R
esolution of all non–immune-related toxicity to Grade ≤ 1 or baseline (with the 
e
xception of alopecia or non–transfusion-dependent anemia). 
N
ote:  Transient asymptomatic laboratory elevations ≤ Grade 3 do not require dose 
i
nterruption or reduction if the participant is asymptomatic and the elevation is 
clinically insignificant and has been discussed with the medical monitor ( eg, amylase, 
lipase). 
 D
aily dose of corticosteroid ≤ [ADDRESS_737869].   
 

Incyte Corporation Page 13 of 84 
Protocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Table 3: Schedule of Activities 
Visit Day (Range)  Screening  Treatment  Follow -Up 
Notes  28 Days  Cycle 1 
Day 1  Cycle ≥  2 
Day 1  
(± 3 d)   Q8W  
(± 7 d)  EOTa Safety  
28-Days After 
Last Dose (± 7 d)  Disease/ 
Survival  
Administrative procedures  
Informed consent  X        
Interactive Response 
Technology  X X X  X    
Inclusion/ex clusion 
criteria  X        
General and disease 
medical history  X        
Prior/concomitant 
medications  X X X  X X   
Administer 
INCMGA [ZIP_CODE]  X X     Premedication with acetaminophen/paracetamol and a histamine 
blocker should be considered for participants who have had 
previous systemic reactions to protein product infusions or when 
recommended by [CONTACT_10569].  
Safety assessments  
AE assessments  X X X  X X X* * Immune -related AEs  to be collected for [ADDRESS_737870] 12 -week follow -up visit with the end of the 90 -day irAE 
reporting period.  
Physical examination  X X X  X X X A comprehensive examination is performed at screening and at 
EOT.  All other scheduled examinations will be targeted.  
Vital signs/body 
weight/height  X X X  X X  Height at screening only.  
12-lead ECG  X X X*   X  * Ever y third cycle (C4, C7, C10, etc ). 
Incyte Corporation Page 14 of 84 
Protocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Table 3: Schedule of Activities (Continued) 
Visit Day (Range)  Screening  Treatment  Follow -Up 
Notes  28 Days  Cycle 1 
Day 1  Cycle ≥  2 
Day 1  
(± 3 d)   Q8W  
(± 7 d)  EOT a Safety  
28-Days After 
Last Dose (± 7 d)  Disease/ 
Survival  
Efficacy assessments  
Tumor imaging/response 
assessments  X   X   X* * Scans during follow -up will only be performed for participants 
continuing to be followed for disease status.   Complete response  
or PR should be confirmed by  [CONTACT_135004] [ADDRESS_737871] study anticancer 
therapy status      X X X  
Survival status      X X X* * During survival follow -up period, participants should be 
contact[CONTACT_5143], email, or visit at least every 12 weeks 
per Section  8.8.3 . 

Incyte Corporation Page 15 of 84 
Protocol INCMGA 0012-202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Table 3: Schedule of Activities (Continued) 
Visit Day (Range)  Screening  Treatment  Follow -Up 
Notes  28 Days  Cycle 1 
Day 1  Cycle ≥  2 
Day 1  
(± 3 d)   Q8W  
(± 7 d)  EOTa Safety  
28-Days After 
Last Dose (± 7 d)  Disease/ 
Survival  
Clinical laboratory assessments  
Blood chemistries  X X* X   X  * Not necessary on C1D1 if performed during screening within 
7 days on C1D1.  
Hematology  X X* X   X  * Not necessary on C1D1 if performed during screening within 
7 days on C1D1.  
Lipid panel  (fasting)  X  X*   X  * Every third cycle (C4, C7, C10, etc) . 
Coagulation panel  X  X*   X  * Every third cycle (C4, C7, C10, etc) . 
Endocrine panel  X  X*   X  * Every third cycle (C4, C7, C10, etc) . 
Urinalysis  X  X*   X  * Every third cycle (C4, C7, C10, etc) . 
Pregnancy testing  X X* X  X** X**  * Not necessary on C1D1 if performed during screening within 
7 days on C1D1.  
** Can be performed at either EOT visit or [ADDRESS_737872] 
dose.  
Timing and type of testing may be adj usted based on 
country -specific requirements.  
a If EOT is ≥ 21 days postdose, the EOT visit will also serve as the 28-day safety follow-up visit.  If EOT is < [ADDRESS_737873] been associated with improved progression-free 
or
 overall survival ( Keytruda® 2017 , Opdivo® 2018 ). 
Squamous cell carcinoma of the anal canal accounts for almost 3% of digestive system cancers 
and is increasing in frequency due to its association with HPV and HIV infection 
(Ghosn et al 2015 ) .  Although most patients have localized disease, systemic metastases will 
develop in approximately 25% of patients, and 5-year survival is poor in these individuals.  
Salvage chemotherapy with platinum-based regimens is an accepted standard of care; however, 
r
esponses are not durable, and progression-free and overall survival after these treatments is 
m
easured only in months.  There are no accepted salvage treatments for patients who progress 
after first-line chemotherapy ( Eng et al 2014 ). 
I
mmunotherapy is a promising new approach to treatment of metastatic SCAC.  The ORR to 
single-agent nivolumab in treatment-refractory SCAC was 24% (95% CI: 15, 33), and most of 
these responses were durable ( Morris et al 2017 ) .  A pi[INVESTIGATOR_561506]-L1+ 
SCAC showed a similar ORR of 17% ( Ott et al 2017 ).  Patients with well-controlled HIV 
infection were included on the nivolumab study, and no unexpected safety issues were reported.  
Anecdotal reports suggest that PD-1 inhibitor treatment may actually improve the outcome of 
chronic HIV infection through multiple mechanisms, includi ng restoration of HIV-specific 
CD8 T-cell function ( Guihot et al 2018 ). 
2.1.1.  INCMGA00012 
The study drug, INCMGA00012, is a humanized, IgG4 monoclonal antibody that recognizes 
human PD-1.  Phase 1 results of INCMGA00012 in patients with advanced cancer (N = 37) have 
been presented ( Lakhani et al 2017 ).  INCMGA00012 demonstrated acceptable tolerability with 
no dose-limiting toxicity observed at doses ranging from 1 to 10 mg/kg Q2W and Q4W.  A 
maximum tolerated dose was not reached.  T ½ (β) was approximately 17 days, and steady-state 
was achieved in approximately 85 days.  Full and sustained receptor occupancy of 
INCMGA00012 on both CD4+ and CD8+ T cells along with complete loss of competing 
fluorescently labeled anti– PD-1 staining (eJBio105 clone) were seen at all dose levels.  
INCMGA00012 is currently being evaluated in expansion cohorts and in combination with other 
potentially immunomodulatory agents. 
Incyte Corporation Page 20 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL INCMGA00012 demonstrated acceptable tolerability with no DLTs observed at any dose level 
up to 10 mg/kg Q2W.  An MTD was not reached.  Treatment-related ≥ Grade 3 AEs occurred in 
4/
37 (10.8%) participants and included increased lipase (n = 3) and vulvovaginal 
u
lceration/inflammation (n = 1).  The most common treatment-related AEs were fatigue (n = 9, 
24.3%
), rash (n = 5, 13.5%), nausea (n = 5, 13.5%), tumor flare (n = 4, 10.8%), and pruritus 
(n 
= 4, 10.8%).  A single, treatment-related SAE of aphasia (occurring in the setting of new brain 
m
etastases) was reported.  Immune-related AEs were limited to rash (n = 5, 13.5%), 
hypothyroidism (n = 3, 8.1%), hyperthyroidism (n = 2, 5.4%), vaginal ulceration/inflammation 
(n 
= 1, 2.7%), and infusion-related reaction (n = 1, 2.7%). 
I
NCMGA00012 is currently being evaluated in tumor-specific expansion cohorts of 
35 participants each in Study INCMGA 0012-101.  The expansion cohorts include cervical 
c
ancer, NSCLC, selected sarcoma subtypes, and endometrial cancer (including microsatellite 
instability-high, mismatch repair deficient, and/or DNA polymerase ε exonuclease domain 
mutation positive disease).  As of [ADDRESS_737874] been treated with 3 mg/kg 
INCMGA00012 in one of the above noted cohorts.  The most frequently reported TEAEs were 
fatigue (13.6%), diarrhea (10.6%), and dyspnea (10.6%).  Forty-six participants (34.8%) had a 
TEAE of ≥ Grade 3; the most frequently reported events of ≥ Grade 3 were colitis, 
h
ypoalbuminemia, and hyponatremia (2.3% each).  Serious AEs occurred in 33 participants 
(25.0%).  SAEs occurring in more than 1 participant included colitis (3.0%), acute kidney injury 
(2.3%), dyspnea (2.3%), and pleural effusion (1.5%).  Immune-related AEs occurred in 
16 participants (12.1%); colitis (2.3%) and infusion-related reaction (2.3%) were the only 
i
mmune-related AEs occurring in more than 1 participant.  INCMGA00012 has also been 
assessed in 2 fixed dose groups (500 mg Q4W and 750 mg Q4W) of [ADDRESS_737875] cancer ( Mehnert et al 2018 ). 
A
s of [ADDRESS_737876] responses has 
be
en observed in multiple tumor types, including all of the disease-specific expansion cohorts 
(previously treated cervical cancer, endometrial cancer, NSCLC, and sarcoma; Mehnert 
et al 2018 ). 
2.2. Rationale for Study Design 
Though initial results with checkpoint inhibitors are encouraging, there still remains an unmet 
medical need in the treatment of SCAC.  In particular, safety, efficacy, and convenience of 
therapy could be improved by [CONTACT_89172][INVESTIGATOR_014], either as monotherapy or as 
pa
rt of rational combination strategies. 
Incyte Corporation Page [ADDRESS_737877] several advantages over weight-based doses, including convenience of 
preparation and administration, reducing errors in preparation calculation, and minimization of 
drug waste.  Body size–based doses and fixed doses of monoclonal antibodies have been 
e
valuated, and the 2 approaches performed similarly, with body size–based doses not always 
of
fering an advantage in reducing variability of exposure ( Wang et al 2009 , B ai et  al 2012 ). 
The proposed flat dose regimen of [ADDRESS_737878]- in-human monotherapy study ([STUDY_ID_REMOVED]).  This dose-escalation 
study of INCMGA00012 was performed and evaluated 37 participants at the following doses:  
1 mg/kg Q2W, 3 mg/kg Q2W, 3 mg/kg Q4W, 10 mg/kg/Q2W, and 10 mg/kg Q4W.  While 
s
upra-dose proportionality was observed for AUC and C max for the first dose from 1 mg/kg to 
10 mg/kg, linear PK was shown from 3 mg/kg to 10 mg/kg.  No dose-limiting toxicity was 
obs
erved with any dose level, and an MTD was not reached. 
A population PK analysis was performed on these participants to characterize the effect of body 
weight on the PK of INCMGA00012.  The serum concentrations of INCMGA00012 can be 
adequately described by a 2-compartment model with first-order elimination.  Higher clearance 
of INCMGA00012 was estimated for 1 mg/kg than the other dose groups.  Body weight 
dependence of clearance was characterized by a power relationship with an exponent of 0.911. 
A simulation was conducted to investigate the use of body weighted dosing and flat dosing for 
INCMGA00012, with the aim of targeting a steady-state trough concentration of approximately 
21 μg/mL, the median trough concentration for pembrolizumab ( F reshwater et al 2017 ).  The 
median INCMGA00012 exposure and its distribution around the median at 500 mg Q4W were 
similar to 7 mg/kg Q4W in the simulated population, which justified clinical exploration in an 
expansion cohort of the study.   The median steady-state concentration at 500 mg Q4W is 
24.8 μg/mL, and 58% of participants have trough concentrations greater than target 
c
oncentration. 
Pharmacokinetic data were obtained from 15 participants who received INCMGA00012 500 mg 
Q4W in the cohort expansion phase of Study INCMGA 0012-101.  The observed AUC 0-∞ for 
500 mg Q4W is close to the steady-state AUC 0 -t based on the population PK analysis of 
weight-based dosing, as is the estimated clearance.  The estimated t ½ (333 h) is slightly shorter 
than that from the previous estimate of 409 hours.  The mean trough serum concentration on 
Cycle 2 was 17.1 μg/mL,  and the mean projected serum C min,ss is 23.1 μg/mL (which meets or 
slightly exceeds the targeted concentration based on pembrolizumab data) with mean 
accumulation index of 1.50.  Overall, the 500 mg Q4W dose had very similar PK properties to 
the 3 mg/kg dosing and has approximately a 58% probability for steady-state trough serum 
c
oncentration ≥ 21 μg/mL, which is associated with maximum target engagement and greatest 
pr
obability of efficacy.  Based on these observations, 500 mg Q4W was chosen as the dose 
regimen as the dosing regimen for this study. 
Incyte Corporation Page 22 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 2.4. Benefit/Risk Assessment 
Treatment directed at the PD-1/PD-L1 axis is a promising approach to SCAC.  Phase 2 results 
with both nivolumab and pembrolizumab in chemotherapy-refractory populations show 
promising efficacy in terms of durable tumor response ( Morris et al 2017 , Ott et al 2017 ).  
Importantly, no unexpected safety findings have been reported in this population, despi[INVESTIGATOR_561507].  Alternative treatments 
(eg, chemotherapy) are associated with both inferior activity and serious toxicities.  Based on 
t
hese observations, the benefit/risk for INCMGA00012 should also be favorable, provided 
efficacy objectives in the proposed study are met. 
Close oversight of study conduct will be provided through safety team meetings and contact [CONTACT_561521].  Additionally, irAEs will be monitored throughout the study as AEs 
of special interest with appropriate guidance provided to investigators for their assessment and 
management. 
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of INCMGA00012 may be found in the IB. 
Incyte Corporation Page 23 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 3. OBJECTIVES AND ENDPOINTS
Table 6 presents the objectives and endpoints. 
T
able 6: Objectives and Endpoints 
Objectives  Endpoints  
Primary  
To assess efficacy of INCMGA00012 in terms of the 
ORR in participant s with locally advanced or metastatic 
SCAC w ho have progressed after  platinum -based 
chemotherapy . ORR, defined as the percentage of participants having a 
CR or PR, according to RECIST v1.1 as determined by 
[CONTACT_89169]. 
Secondary  
To determine additional measures of clinical benefit, 
specifically, DOR, DCR,  PFS, and OS.  DOR, defined as the time from an initial objective 
response (CR or PR) according to RECIST v1.[ADDRESS_737879] dose of study 
treatment  until disease progression by [CONTACT_561522].  
OS, defined as the time from the start of therapy until 
death due to any cause.  
To evaluate the  safety of INCMGA00012 in participants 
with previously -treated SCAC . Safety, determined by [CONTACT_431985] s; the 
frequency, duration, and severity of AEs  per CTCAE 
v5.0; laboratory tests ; vital signs ; and ECGs . 
To determine the PK of INCMGA00012  administered to 
participant s with SCAC . Population PK, including C max, Tmax, Cmin, and AUC 0-t, 
will be summarized.  

Incyte Corporation Page [ADDRESS_737880] v1.1. 
The study consists of 3 periods:  screening, study drug treatment, and follow-up.  Treatment may 
c
ontinue for up to 2 years in the absence of clinical disease progression (see Section 8.2), 
intolerable toxicity, death, withdrawal of consent, lost to follow-up, or premature discontinuation 
for any other reason. 
Treatment will be administered by [CONTACT_12781] 60 minutes (±15 minutes) on Day 1 of each 
28-day cycle.  Subsequent treatment cycles should be delayed (for up to 12 weeks, see 
S
ection 6.5) until the following criteria are met: 
 Hemoglobin ≥ 8 gm/dL. 
 A
NC ≥ 1.0 × 109/L. 
 Platelet count ≥ 75 × 109/L. 
 A
LT/AST/bilirubin ≤ Grade 2. 
 R
esolution of all immune-related toxicity to ≤ Grade 1 (with the exception of 
endocrinopathy that is controlled on hormonal replacement), other than unacceptable 
toxicity per Section 6.5. 
 R
esolution of all non–immune-related toxicity to Grade ≤ 1 or baseline (with the 
e
xception of alopecia or non–transfusion-dependent anemia). 
N
ote:  Transient asymptomatic laboratory elevations ≤ Grade 3 do not require dose 
i
nterruption or reduction if the participant is asymptomatic and the elevation is 
clinically insignificant and has been discussed with the medical monitor ( eg, amylase, 
lipase). 
 D
aily dose of corticosteroid ≤ 10 mg prednisone or equivalent. 
Participants unable to restart study drug treatment ≤ 12 weeks from the start of the treatment 
delay due to toxicity will be permanently discontinued from study treatment.  Treatment 
i
nterruptions of > 12 weeks for reasons other than toxicity (eg, for targeted radiotherapy or 
s
urgical resection of oligometastatic disease) will be considered on a case-by-case basis by [CONTACT_35041].   
Participants who have been treated for at least [ADDRESS_737881] v1.1 (see Section 8.2.1 )  
 with the decision to treat beyond conventional RECIST progression documented 
in the study file. 
The follow-up period will begin once a participant has completed [ADDRESS_737882] dose of study drug, regardless of whether a new anticancer therapy is started. 
O
nce participants discontinue treatment, they enter the follow-up period and will be assessed for 
s
urvival until study completion.  Participants who discontinue study treatment without 
experiencing disease progression will enter the follow-up period and continue to undergo tumo r 
assessments according to the schedule of activities (see Table 3 )  until they experience disease 
progression, the start of a new anticancer treatment, withdrawal of consent, lost to follow-up, the 
end of the study, or death. 
The complete study-specific assessment schedule required for participants in this clinical study is 
presented in Table [ADDRESS_737883] completed the study if he/she has completed all periods/parts 
of the study including survival follow-up. 

Incyte Corporation Page [ADDRESS_737884].  The investigator is to notify the IRB/IEC in writing of the 
study's completion or early termination, send a copy of the notification to the sponsor or 
sponsor's designee, and retain [ADDRESS_737885] of the study.  The establishment, composition, roles, duties, and 
responsibilities of the DMC will be addressed in the DMC Charter. 
Preplanned analyses of safety will be provided to the independent DMC as specified in the DMC 
Charter.  In addition, the DMC will make recommendations to the sponsor at a planned interim 
analysis.  In terms of efficacy, the DMC will use the guidelines provided for recommendation of 
e
ither continuation or early termination of the study at the interim analysis.  Additionally, the 
DMC will review safety data of the ongoing study at regular intervals as specified in the DMC 
Charter.  The process by [CONTACT_561523]. 
Incyte Corporation Page 27 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 5. STUDY POPULATION 
Deviations from eligibility criteria are not allowed, because they can potentially jeopardize the 
s
cientific integrity of the study, regulatory acceptability, and/or participant safety.  Therefore, 
a
dherence to the criteria as specified in the Protocol is essential.  Prospective approval of 
P
rotocol deviations to recruitment and enrollment criteria, also known as Protocol waivers or 
exemptions, are not permitted. 
5.1. Inclusion Criteria 
Participants are eligible to be included in the study only if all of the following criteria apply: 
1. Ability to comprehend and willingness to sign a written ICF for the study. 
2. Men and women 18 years of age or older (or as applicable per local country 
requirements). 
3. Confirmed diagnosis of locally advanced or metastatic SCAC. 
4. Participants must have had progression on or after platinum-based therapy unless 
ineligible for or intolerant of platinum. 
a. No more than [ADDRESS_737886] 1 prior line of 
s
ystemic therapy. 
c. Participants receiving platinum-based radiosensitizing chemotherapy are eligible if 
relapse occurs < [ADDRESS_737887] also 
be met: 
a. CD4+ count ≥ 300/μL. 
b. Undetectable viral load. 
c. R
eceiving antiretroviral therapy (ART). 
8. W
illingness to avoid pregnancy or fathering children based on the criteria below. 
a. Men must agree to take appropriate precautions to avoid fathering children (with at 
least 99% certainty) from screening through [ADDRESS_737888] dose of study drug 
(or longer as appropriate based on country-specific requirements) and must refrain 
from donating sperm during this period.  Permitted methods that are at least 
99% effective in preventing pregnancy (see A ppendix A ) should be communicated to 
the participants and their understanding confirmed. 
Incyte Corporation Page [ADDRESS_737889] agree to take appropriate precautions to avoid pregnancy (with at 
least 99% certainty) from screening through [ADDRESS_737890] 99% effective in preventing pregnancy 
(see Appendix A ) should be communicated to the participants and their understanding 
confirmed. 
c. Women of nonchildbearing potential ( ie, surgically sterile with a hysterectomy and/or 
bilateral oophorectomy OR ≥ [ADDRESS_737891] 50 years of age) 
a
re eligible. 
9.  
 
 
5.2. Exc
lusion Criteria 
Participants are excluded from the study if any of the following criteria apply: 
1. Receipt of anticancer therapy or participation in another interventional clinical study 
within [ADDRESS_737892] administration of study drug; [ADDRESS_737893] dose of study treatment with the following caveats:  
a. 28 days for pelvic radiotherapy. 
b. 6 months for thoracic region radiotherapy that is > 30 Gy in 2 Gy fractions. 
3. Prior treatment with PD-1 or PD-L1 directed therapy (other immunotherapi[INVESTIGATOR_561508]). 
4. Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the 
exception of any grade of alopecia and anemia not requiring transfusion support).   
Endocrinopathy, if well-managed, is not exclusionary and should be discussed with 
sponsor medical monitor. 
5. Participants with laboratory values at screening defined in Table 7 . 

Incyte Corporation Page 29 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Table 7: Exclusionary Laboratory Values 
Laboratory Parameter  Exclusion Criterion  
Hematology  
a Platelets  ≤ 75 × 109/L 
b Hemoglob in ≤ 9 g/dL 
c ANC   ≤ 1.5 × 109/L 
Hepatic  
d ALT > 2.5 × ULN  OR > 5 × ULN for participants with liver metastases  
e AST > 2.5 × ULN  OR > 5 × ULN for participants with liver metastases  
f Bilirubin  ≥ 1.5 × ULN unless conjugated bilirubin ≤ ULN (conjugated bilirubin only 
needs to be tested if total bilirubin exceeds ULN).  If there is no 
institutional ULN, then direct bilirubin must be <  40% of total bilirubin . 
Renal  
g Calculated creatinine clearance  < 30 mL/min  
Coagulation  
h INR or PT  > 1.5 × ULN , for participant s not receiving anti coagulant therapy  
i aPTT  > 1.5 × ULN  for participant s not receiving anti coagulant therapy  
6. Known additional malignancy that is progressing or requires active treatment, or history 
of other malignancy within 3 years of study entry with the exception of cured basal cell 
or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepi[INVESTIGATOR_561509], carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, 
or cancers from which the participant has been disease-free for > 1 year, after treatment 
with curative intent. 
7. Active autoimmune disease requiring systemic immunosuppression in excess of 
physiologic maintenance doses of corticosteroids (> 10 mg of prednisone or equivalent). 
8. E
vidence of interstitial lung disease or active noninfectious pneumonitis. 
9. K
nown active CNS metastases and/or carcinomatous meningitis.  
Note:   Participants with previously treated brain metastases may participate provided they 
are stable (without evidence of progression by [CONTACT_89181] [ADDRESS_737894] returned to baseline), have no 
evidence of new or enlarging brain metastases or CNS edema, and have not required 
steroids for at least [ADDRESS_737895] dose of study drug. 
10. K
nown active HAV , HBV, or HCV infection, as defined by [CONTACT_561524]:  positivity for HAV IgM antibody, anti-HCV, anti-HBc IgG or 
I
gM, or HBsAg (in the absence of prior immunization). 
11. Active infections requiring systemic therapy. 
12. Known hypersensitivity to another monoclonal antibody that cannot be controlled with 
standard measures ( eg, antihistamines and corticosteroids) or known allergy or 
hypersensitivity to any component of INCMGA00012 or formulation components. 
Incyte Corporation Page 30 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 13. Participants with impaired cardiac function or clinically significant cardiac disease: 
a. [LOCATION_001] Heart Association Class III or IV cardiac disease, including preexisting 
clinically significant ventricular arrhythmia, congestive heart failure, or 
cardiomyopathy.  
b. Unstable angina pectoris. 
c. A
cute myocardial infarction ≤ 6 months before study participation. 
d. O
ther clinically significant heart disease ( ie, ≥ uncontrolled Grade 3 hypertension.)  
14. Participant is pregnant or breastfeeding. 
15. Participant is expecting to conceive or father children within the projected duration of the 
study, from screening through [ADDRESS_737896] dose of study drug. 
16. P
articipant has not recovered adequately from toxicities and/or complications from 
surgical intervention before starting study drug. 
17. H
as received a live vaccine within 28 days of the planned start of study drug. 
N
ote:  Examples of live vaccines include, but are not limited to, the following:  measles, 
mumps, rubella, chicken pox/zoster, yellow fever, rabies, BCG, and typhoid vaccine.  
Seasonal influenza vaccines for injection are generally killed virus vaccines and are 
allowed; however, intranasal influenza vaccines ( eg, FluMist®)  are live-attenuated 
vaccines and are not allowed. 
18. Current use of prohibited medication as described in Section 6.6.2 . 
19. Any condition that would, in the investigator's judgment, interfere with full participation 
in the study, including administration of study drug and attending required study visits; 
pose a significant risk to the participant; or interfere with interpretation of study data. 
5.3. Lifestyle Considerations 
Not applicable. 
[ADDRESS_737897] reconsent and be assigned a new participant number. 
5.5. Replacement of Participants 
Not applicable. 
Incyte Corporation Page 31 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 6. STUDY TREATMENT 
6.1. Study Treatments Administered 
Table 8 presents the study drug informatio n. 
T
able 8: Study Drug Information 
Study drug  name:  [CONTACT_89234] [ZIP_CODE]  
Dosage formulation:  liquid formulation  
Unit dose strength/dosage level : 500 mg Q4W  
Route of  administration:  IV 
Administration instructions:  Administ ered IV over 60  minutes  (±15 min utes) 
Packaging and labeling:  INCMGA00012 will be provided in a 250  mg vial. 
Each vial will be labeled as required per country requirement.  
Storage:  Upright under refrigeration at 2°C -8°C (36°F -46°F)  
Protected from light  
6.2. Preparation , Handling, and Accountability 
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study drug received and any discrepancies are reported and 
resolved before use of the study drug. 
O
nly participants enrolled in the study may receive study drug, and only authorized site staff 
m
ay supply or administer study drug.  All study drug must be stored in a secure, environmentally 
controlled, and monitored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff. 
The investigator (or designee) is responsible for study drug accountability, reconciliation, and 
record maintenance (i e, receipt, reconciliation, and final disposition records).  Inventory and 
a
ccountability records must be maintained and readily available for inspection by [CONTACT_319853].  The 
investigator or designee must maintain records that document: 
 Delivery of study drug(s) to the study site. 
 Inventory of study drug(s) at the site. 
 P
articipant use of the study drug(s) including tablet and vial counts (as appropriate for 
each study drug) from each supply dispensed. 
 Lot numbers and/or vial numbers (as applicable) of study drug used to prepare the 
infusion solution. 
 Return of study drug(s) to the investigator or designee by [CONTACT_4317]. 
Incyte Corporation Page [ADDRESS_737898] and retain all used, unused, and partially used containers of study drug 
until verified by [CONTACT_11200] (unless otherwise agreed to by [CONTACT_456]).  At the 
conclusion of the study, the investigator or designee will oversee shipment of any remaining 
study drug back to the sponsor or its designee for destruction according to institutional SOPs.  If 
local procedures mandate on-site destruction of investigational supply, the site should (where 
local procedures allow) maintain the investigational supply until the study monitor inspects the 
accountability records in order to evaluate compliance and accuracy of accountability by [CONTACT_198373].  At sites where the study drug is destroyed before monitor inspection, the 
m
onitors rely on documentation of destruction per the site SOP. 
Further guidance and information for the final disposition of unused study drug are provided in 
the Pharmacy Manual. 
6.3. Measures to Minimize Bias:  Randomization and Blinding 
Not applicable. 
6
.4. Study Treatment Compliance 
Compliance with all study-related treatments should be emphasized to the participant by [CONTACT_89184], and appropriate steps should be taken to optimize compliance during the study.  
Compliance with study drug will be calculated by [CONTACT_561525]/designee. 
6.5. Dose Modifications 
Dose reduction is not allowed.  Before the start of each treatment cycle, the participant must 
meet the treatment continuation criteria in Section 4.1. 
Infusion or hypersensitivity reactions may be observed with administration of any foreign 
protein.  Premedication with acetaminophen/paracetamol and a histamine blocker should be 
considered for participants who have had previous systemic reactions to protein product 
infusions or when recommended by [CONTACT_10569]. 
Guidelines for management of suspected infusion reactions are provided in Table 9. 
Incyte Corporation Page 33 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Table 9: Guidelines for Management of Suspected Infusion Reactions 
Grade  Descriptiona Treatment  Subsequent Infusions  
1 Mild reaction; infusion interruption 
not indicated; intervention not 
indicated . Monitor vital signs closely until 
medically stable . Premedication with 
acetamin ophen/paracetamol 
and a histamine blocker 
should be considered for 
participants who have had 
previous systemic reactions 
to protein product infusions 
or when recommended by 
[CONTACT_10569].  
2 Requires infusion interruption but 
responds promp tly to sy mptomatic 
treatment ( eg, antihistamines, 
NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated 
for ≤ [ADDRESS_737899] occurrence:   Stop infusion 
and initiate appropriate medical 
measures ( eg, IV fluids, 
antihistamines NSAIDS, 
acetaminophen /paracetamol , 
narcotics, per institutional 
preferences).  
Monitor vital signs until medically 
stable . 
If symptoms reso lve within 1 hour, 
infusion may be resumed at 50% 
of the original infusion rate . 
Subsequent occurrences (after 
recommended prophylaxis):   
Permanently discontinue 
treatment.  Premedicate at least 
30 minutes before  infusion 
with antihistamines 
(eg, diphenhydr amine 50  mg 
PO) and 
acetaminophen /paracetamol  
(500 -1000  mg PO). 
Additional supportive 
measures may be acceptable 
(per institutional preference) 
but sh ould be discussed with 
medical m onitor . 
3 or 4  Grade 3:   Prolonged ( ie, not rapi[INVESTIGATOR_561510]/or brief interruption 
of infusion); recurrence of 
symptoms following initial 
improvement; hospi[INVESTIGATOR_80028] 
(eg, renal impairment, pulmonary 
infiltrates).  
Grade 4:   Life-threatening; pressor 
or ventil atory support indicated.  Stop infusion and initiate 
appropriate medical therapy 
(eg, IV fluids, antihistamines 
NSAIDS, 
acetaminophen /paracetamol , 
narcotics, oxygen, pressors, 
epi[INVESTIGATOR_238], corticosteroids, per 
institutional preferences).  
Monitor vital signs  frequently until 
medically stable.  Hospi[INVESTIGATOR_561511].  Discontinue study drug . 
a Per NCI CTCAE v5.0, appropriate resuscitation equipment should be available at the bedside and a physician readily available 
during the period of study drug administration. 
Incyte Corporation Page [ADDRESS_737900] dose of treatment. 
If an irAE is suspected, efforts should be made to rule out neoplastic, infectious, metabolic, 
toxin, or other etiologic causes before labeling an AE as an irAE. 
R
ecommendations for management of specific immune-mediated AEs known to be associated 
with other PD-1 inhibitors ( eg, pembrolizumab, nivolumab) are detailed in the sections below. 
Management guidance for irAEs not detailed elsewhere in the Protocol should follow the ASCO 
Clinical Practice Guideline ( Brahmer et al 2018 ), provided in the Study Procedures Manual. 
[IP_ADDRESS].  I
mmune-Mediated Pneumonitis 
Participants with symptomatic pneumonitis should immediately stop receiving study drug and 
have an evaluation.  The evaluation may include bronchoscopy and pulmonary function tests to 
rule out other causes such as infection.  If the participant is determined to have study 
drug–associated pneumonitis, the suggested treatment plan is detailed in T able 10. 
T
able 10: Recommended Approach to Handling Pneumonitis 
Study Drug –Associated 
Pneumonitis  Withhold/Discontinue  Study Drug  
Criteria for restarting study drug are 
in Section  4.1. Supportive Care  
Grade 1 (asymptomatic)  No action.  Intervention not indicated.  
Grade 2  Withhold study drug.   Syste mic corticosteroids are indica ted (initial 
dose of 1 -2 mg/kg per day of prednisone or 
equivalent).  Taper as appropriate.  
Grades 3 and 4  or 
recurrent Grade 2  Permanently discontinue study drug. Systemic corticosteroids are indicated.  
[IP_ADDRESS].  Immune-Mediated Colitis 
Participants should be carefully monitored for signs and symptoms of colitis (such as diarrhea, 
abdominal pain, mucus, or blood in stool, with or without fever).  In symptomatic participants, 
infectious etiologies should be ruled out, and endoscopic evaluation should be considered for 
persistent or severe symptoms.  Recommendations for management of enterocolitis are shown in 
Table 11. 
Incyte Corporation Page 35 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Table 11: Recommended Approach for Handling Enterocolitis/Diarrhea 
Study Drug –Associated 
Enterocolitis/Diarrhea  Withhold/Discontinue  Study Drug  
Criteria for restarting study drug are 
located in Section  4.1. Supportive Care  
Grade [ADDRESS_737901] udy drug. Systemic corticosteroids a re indicated (initial 
dose of 1  mg/kg to 2 mg/kg per day of 
prednisone or equivalent).  Taper as 
appropriate.  Treatment with infliximab is 
acceptable per institutional guidelines.  
Grade 3  Withhold study drug.  Treatmen t with systemic corticosteroids 
should be initiated.  Treatment with infliximab 
is acceptable per institutional guidelines.  Grade 4 or recurrent 
Grade 3  Permanently discontinue study drug.  
[IP_ADDRESS].  Immune-Mediated Hepatitis 
Liver chemistry testing (hepatic transaminase and bilirubin levels) should be monitored and 
participants assessed for signs and symptoms of hepatotoxicity before each dose of 
INCMGA00012.  In participants with hepatotoxicity, infectious or malignant causes should be 
ruled out, and frequency of liver chemistry monitoring should be increased until resolution.  
Recommendations for management of hepatitis are shown in Table 12 . 
Table 12: Recommended Approach for Handling Hepatitis 
Stud y Drug –Associated 
Hepatitis  Withhold/Discontinue  Study Drug  
Criteria for restarting study drug are 
located in Section  4.1. Supportive Care  
Grade 1  No action.  Increase frequency of liver chemistry  
monitoring to twice per week until liver 
chemistry tests return to baseline.  
Grade 2  Withhold study drug. Systemic corticosteroids are indicate d (initial 
dose of 0.5  mg/kg to 1 mg/kg per day of 
prednisone or equivalent).  Taper as 
appropriate.  
Grades 3 and 4  Permanently discontinue study drug. Treatment with systemic corticosteroids should 
be initiated (initial dose of 1  mg/kg to 2 mg/kg 
per day of prednisone or equivalent).  Taper as 
appropriate.  
Incyte Corporation Page 36 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL [IP_ADDRESS].  Immune-Mediated Endocrinopathies 
[IP_ADDRESS].1.  Hypophysitis 
Monitor for signs and symptoms of hypophysitis (including hypopi[INVESTIGATOR_19341]).  Recommendations for management of hypophysitis are shown in Table 13 . 
Table 13: Recommended Approach for Handling Hypophysitis 
Study Drug –Associated 
Hypophysitis  Withhold/Discontinue  Study Drug  
Criteria for restarting study drug are 
located in Section  4.1. Supportive Care  
Grade 1  No action.  Administer corticosteroids and hormone 
replacement as clinically indicated.  Grade 2  Withhold study drug.  
Grade 3  Withhold or discontinue study drug.  
Grade 4  Permanently discontinue study drug.  
[IP_ADDRESS].2.  Thyroid Disorders 
Monitor participants for changes in thyroid function (at the start of treatment, periodically during 
treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of 
thyroid disorders.  Recommendations for management of thyroid disorders are shown in 
Table 14. 
T
able 14: Recommended Approach for Handling Thyroid Disorders 
Study Drug –Associated 
Thyroid Disorders  Withhold/Discontinue  Study Drug  
Criteria for restarting study drug are 
locate d in Section  4.1. Supportive Care  
Grades 1 and 2  No action.  Administer replacement hormones for 
hypothyroidism and manage hyperthyroidism 
with thionamides and beta -blockers as 
appropriate.  Grade 3  Withhold or d iscontinue study drug.  
Grade 4  Permanently discontinue study drug.  
[IP_ADDRESS].3.  New Onset Diabetes Mellitus 
Monitor participants for hyperglycemia or other signs and symptoms of diabetes.  
R
ecommendations for management of diabetes mellitus are shown in Table 15 . 
Table 15: Recommended Approach for Handling New Onset Diabetes Mellitus 
Study Drug –Associated 
Diabetes Mellitus  Withhold/Discontinue S tudy Drug  
Criteria for restarting study dru g are 
located in Section  4.1. Supportive Care  
Grade s 1 and 2 No action.  Intervention not indicated.  
Grade 3  Withhold study drug.  Administer insulin for Type 1 diabetes and 
administer antihyperglycemics in parti cipants 
with severe hyperglycemia.  Grade 4  Permanently discontinue study drug.  
Incyte Corporation Page 37 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL [IP_ADDRESS].  Immune-Mediated Nephritis and Renal Dysfunction 
Monitor participants for changes in renal function.  Recommendations for management of 
nephritis and renal dysfunction are shown in Table 16 .  
Table 16: Recommended Approach for Handling Nephritis and Renal Dysfunction 
Study Drug –Associated 
Nephritis and Renal 
Dysfunction  Withhold/Discontinue  Study Dru g 
Criteria for restarting study drug are 
located in Section  4.1. Supportive Care  
Grade 1  No action.  Intervention not indicated.  
Grade 2  Withhold study drug.  Treatment with systemic corticosteroids should 
be ini tiated (initial dose of 1  mg/kg to 2  mg/kg 
per day of prednisone or equivalent).  Taper as 
appropriate.  Grades 3 or 4  Permanently discontinue study drug.  
[IP_ADDRESS].  Immune-Mediated Skin Reactions 
Immune-mediated rashes, including Stevens-Johnson syndrome, toxic epi[INVESTIGATOR_194] 
(some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur.  
Monitor participants for suspected severe skin reactions and exclude other causes.  
Recommendations for management of skin reactions are shown i n Table 17 . 
Table 17: Recommended Approach for Handling Skin Reactions 
Study Drug –Associated 
Skin Reactions  Withhold/Discontinue S tudy Drug  
Criteria for restarting study drug a re 
located in Section  4.1. Supportive Care  
Grade 1  No action.  Intervention not indicated.  
Grade 2  Withhold study drug.  Treatment with systemic corticosteroids 
should be initiated (initial dose of 1  mg/kg to 
2 mg/kg per day of prednisone or equivalent).  
Taper as appropriate.  
Note:   May consider IV immunoglobulin 
(IVIG) or cyclosporine as an alternative or in 
corticosteroid -refractory cases, for Grade for 
SCARs, DRESS/DIHS.  Grade 3 or suspected 
Stevens -Johnson 
syndrome or toxic 
epi[INVESTIGATOR_561512].  
Grade  4 or confirmed 
Stevens -Johnson 
syndrome or toxic 
epi[INVESTIGATOR_561513].  
[IP_ADDRESS].  Immune-Mediated Myocarditis 
Immune-mediated myocarditis can occur (some cases with fatal outcome).  Monitor participants 
for suspected myocarditis and exclude other causes.  Recommendations for management of 
myocarditis are shown in Table 18 . 
Incyte Corporation Page 38 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Table 18: Recommended Approach for Handling Myocarditis 
Study Drug –Associated 
Myocard itis Withhold/Discontinue Study Drug  
Criteria for restarting study drug are 
located in Section  4.1. Supportive Care  
Grade s 2, 3, and 4 Perma nently discontinue study drug.  Upon signs and symptoms, all grades warrant 
work -up and intervention given potential for 
cardiac compromise . 
Treatment with systemic corticosteroids 
should be initiated (initial dose of 1  mg/kg to 
2 mg/kg per day of prednison e or equivalent).   
Taper as appropriate.  
Management of cardiac symptoms  according 
to standard of care  and with guidance from 
cardiology .  Consider cardiac MRI and 
myocardial biopsy for diagnosis.  
6.5.2.  Permanent Discontinuation of Study Drug Due to Toxicity 
The occurrence of unacceptable toxicity not caused by [CONTACT_561526].  Unacceptable toxicity is defined as follows: 
 Occurrence of an AE that is related to study treatment that, in the judgment of the 
investigator or the sponsor's medical monitor, compromises the participant's ability to 
continue study-specific procedures or is considered to not be in the participant's best 
interest. 
 Persistent AE requiring a delay of therapy for more than 12 weeks. 
 Any AE defined in the dose modifications management guidelines (see Section 6.5) 
requiring the study treatment be discontinued. 
A complete list of study treatment discontinuation reasons and procedures is found in Section 7. 
6
.6. Concomitant Medications and Procedures 
All concomitant medications and treatments (including over-the-counter or prescription 
medicines, vitamins, vaccines, and/or herbal supplements) must be recorded in the eCRF.  Any 
medication received up to [ADDRESS_737902] 
dos
e of study drug (unless associated with the treatment of an AE), or until the participant begins 
a new anticancer therapy, whichever occurs first, will be recorded in the eCRF.  Any addition, 
deletion, or change in the dose of these medications will also be recorded.  Concomitant 
medications administered for the management of SAEs or irAEs should be recorded regardless 
of when they are provided.  Concomitant treatments/procedures that are required to manage a 
pa
rticipant's medical condition during the study will also be recorded in the eCRF.  The medical 
m
onitor should be contact[CONTACT_31182]. 
Incyte Corporation Page 39 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 6.6.1.  Permitted Medications and Procedures 
Antiretroviral therapy (ART) should be continued for participants who are known to be 
HIV-positive. 
Recommended supportive measures for specific toxicities are described in Section 6.5. 
G
rowth factors, bisphosphonates, anticoagulants, and transfusional support will also be permitted 
and must be reported into the eCRF. 
Premedication with acetaminophen/paracetamol and a histamine blocker should be considered 
for participants who have had previous systemic reactions to protein product infusions or when 
recommended by [CONTACT_10569]. 
6.6.2.  Prohibited Medications and Procedures 
 Other anticancer therapi[INVESTIGATOR_014], including investigational treatments within [ADDRESS_737903] administration of study drug (6 weeks for mitomycin C), and throughout the 
treatment period of the study. 
 I
mmunosuppression in excess of physiologic maintenance corticosteroid doses 
(> 10 mg of prednisone or equivalent ) w ithin [ADDRESS_737904] dose and throughout the 
treatment period of the study (with the exception of acute treatment for an AE). 
 Probiotic dietary supplements. 
 Live vaccines within [ADDRESS_737905]
ug. 
Note:   Examples of live vaccines include, but are not limited to, the following:  
measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, BCG, and typhoid 
vaccine.  Seasonal influenza vaccines for injection are generally killed virus vaccines 
and are allowed; however, intranasal influenza vaccines ( eg, FluMist®) are 
live-attenuated vaccines and are not allowed. 
6.7. Treatment After the End of the Study 
Once a participant has discontinued study treatment, no further treatment will be provided in this 
study.  Participants who discontinue study drug will enter the follow-up period to be evaluated 
for safety and survival.  Any participants entering the follow-up period for any reason other than 
PD will continue to be evaluated for disease status according to the scheduled assessments found 
in Table 3 . 
Incyte Corporation Page 40 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 7. DISCONTINUATION OF STUDY TREATMENT AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL 
7.1. Discontinuation of Study Drug 
7.1.1.  Reasons for Discontinuation 
Participants must  be withdrawn from study drug for the following reasons: 
 Clinical disease progression. 
 Unacceptable toxicity as noted in Section 6.5.2 . 
 C
onsent is withdrawn. 
N
ote:  Consent withdrawn means that the participant has explicitly indicated that they 
do not want to participate in the study or be followed any longer; in this case no 
further data, except data in public domain, may be solicited from or collected on the 
participant.  Participants who discontinue study drug will remain in the study to be 
f
ollowed for progression and survival. 
 Further study treatment would be injurious to the participant's health or well-being, in 
the investigator's medical judgment. 
 The study is terminated by [CONTACT_456]. 
 The study is terminated by [CONTACT_19407], IRB, or IEC. 
A participant  may be discontinued from study drug as follows:  
 The participant becomes pregnant.  If the female participant is no longer pregnant and 
meets the treatment continuation criteria within 12 weeks of the scheduled start of a 
cycle, study treatment may be resumed after approval has been received from the 
medical monitor (see Section 9.7). 
 If a participant is noncompliant with study procedures or study drug administration in 
the investigator's opi[INVESTIGATOR_1649], the sponsor should be consulted for instruction on handling 
the participant. 
Incyte Corporation Page [ADDRESS_737906] dose of study drug 
a
nd the reason for discontinuation of study drug will be recorded in the eCRF. 
If a participant is discontinued from study drug: 
 The study monitor or sponsor must be notified. 
 The reason(s) for discontinuation from study drug must be documented in the 
participant's medical record, and the primary reason must be included in the eCRF. 
 T
he EOT visit should be performed. 
 The date of the EOT visit should be recorded in the IRT. 
 After the EOT visit, participants will remain in the study to be followed for 
progression and survival and will be followed for safety and AEs per Sections 8.8 
a
nd 9. 
D
iscontinuation from study drug does not mean withdrawal from the study, and remaining study 
procedures should be completed as indicated by [CONTACT_561527].  
If the participant discontinues study drug, the participant will complete the EOT visit and move 
into the follow-up portion of the study pe r Table 3.  However, if a participant actively withdraws 
c
onsent for collection of follow-up data (safety follow-up or disease assessment), then no 
additional data collection should occur (with the exception of data in the public domain.) 
7.2. Participant Withdrawal From the Study 
A participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the investigator for safety, behavioral, compliance, or 
administrative reasons. 
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent. 
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records. 
See Table [ADDRESS_737907] to follow-up if he/she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298]. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit: 
 The site must attempt to contact [CONTACT_288949]/or 
should continue in the study. 
 Before a participant is deemed lost to follow-up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, [ADDRESS_737908] 1 certified letter to the participant's last known mailing address or 
l
ocal equivalent methods).  These contact [CONTACT_21457]'s medical record. 
 Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Incyte Corporation Page 43 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 8. STUDY ASSESSMENTS AND PROCEDURES 
8.1. Administrative and General Procedures 
8.1.1.  Informed Consent Process 
 The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally authorized representative and answer all questions 
regarding the study. 
 Informed consent must be obtained before any study-related procedures are 
conducted, unless otherwise specified by [CONTACT_89191]. 
 Informed consent must be obtained using the IRB/IEC-approved version in a 
language that is native and understandable to the participant.  A template will be 
provided by [CONTACT_3552].  The sponsor or its designee must review 
and acknowledge the site-specific changes to the ICF template.  The ICF must 
include a statement that the sponsor or its designee and regulatory authorities have 
direct access to participant records. 
 The ICF must contain all required elements and describe the nature, scope, and 
possible consequences of the study in a form understandable to the study 
participant. 
 Participants must be informed that their participation is voluntary.  Participants or 
their legally authorized representative will be required to sign a statement of informed 
consent that meets the applicable requirements and regulations for the countries in 
which the study is being conducted as well as the IRB/IEC or study center. 
 The participant must be informed that his/her personal study-related data will be used 
by [CONTACT_89192].  The level of disclosure 
must also be explained to the participant. 
 The participant must be informed that his/her medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_9326]. 
 The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained.  The authorized person obtaining the informed consent must 
also sign the ICF. 
 Participants must provide consent to the most current version of the ICF(s) during 
their participation in the study 
  
 
 A copy of 
the ICF(s) must be provided to the participant or the participant's legally 
authorized representative. 
Participants who are rescreened are required to sign a new ICF. 
 

Incyte Corporation Page 44 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 8.1.2.  Screening Procedures 
Screening is the interval between signing the ICF and the day the participant is enrolled in the 
study (Cycle 1 Day 1).  Screening may not exceed 28 days.  Assessments that are required to 
de
monstrate eligibility may be performed over the course of 1 or more days during the screening 
pr
ocess. 
Procedures conducted as part of the participant's routine clinical management ( eg, blood count, 
imaging study) and obtained before signing of informed consent may be used for screening or 
baseline purposes provided the procedure meets the Protocol-defined criteria and has been 
performed in the timeframe of the study ( ie, within 28 days of Cycle 1 Day 1).  For participants 
who are enroll ed in the study, information associated with eligibility requirements must be 
entered into the appropriate eCRF pages. 
Tests with results that fail eligibility requirements may be repeated.  For screening assessments 
that are repeated, the most recent available result before treatment assignment will be used to 
determine eligibility. 
See Sections 5.[ADDRESS_737909] the IRT to obtain the participant ID 
number.  Additionally, the IRT will be contact[CONTACT_561528] ( eg, completion or premature discontinuations as well as to update the study drug 
s
upply.  Additional details are provided in the IRT manual. 
8.1.4.  Distribution of Reminder Cards 
Participants will be provided with a reminder card at each visit.  The reminder card will indicate 
t
he date/time of the next visit and will also inform the participant about visit-specific procedures. 
8.1.5.  D
emography and Medical History 
[IP_ADDRESS].  Demographics and General Medical History 
Demographic data and general medical history will be collected at screening by [CONTACT_561529], race, ethnicity, medical and surgical history, and 
current illnesses. 
[IP_ADDRESS].  Disease Characteristics and Treatment History 
A disease-targeted medical and treatment history will be collected at screening.   Details 
regarding the participant's malignancy under study, including date of diagnosis, initial and 
c
urrent cancer stage, tumor histology, and relevant disease characteristics, and prior treatments, 
including systemic treatments, radiation, and surgical procedures, will be recorded. 
Incyte Corporation Page [ADDRESS_737910] v1.1 ( Eisenhauer 
et al 2009 ) and entered into the eCRF.   
 
Efficac
y assessments of response should be performed according to schedule found in Table 3.  
S
cans should follow calendar days and remain on the 8-week schedule, established on Cycle [ADDRESS_737911] v1.1 guidelines ( E isenhauer et al 2009 ) as described in Appendix B .  The recommended 
method for measuring and following tumor burden will be CT scan, which should be performed 
using consistent techniques and facilities.   The CT portion of PET-CT may be acceptable if it is 
of identical diagnostic quality to a diagnostic CT (with IV and oral contrast.)  Alternative 
modalities such as MRI may be substituted for a CT scan at the discretion of the investigator, 
provided that the same modality is used throughout the study and the methodology is consistent 
with RECIST v1.1.  Initial tumor imaging must be performed within [ADDRESS_737912], 
abdomen, and pelvis are required for all participants.  Imaging of other anatomical sites (ie, head, 
neck, and extremities) should be performed as applicable if participant has disease or suspected 
disease in those areas. 
Computed tomography or MRI scan of the brain will be performed at screening if there are signs 
or symptoms suggesting that the participant has disease involvement in the CNS. 

Incyte Corporation Page [ADDRESS_737913]
ug.  Conditions that were already present at the time of informed consent should be recorded 
on the Medical History Form in the eCRF.  Adverse events (including laboratory abnormalities 
that constitute AEs) should be described using a diagnosis whenever possible rather than by 
[CONTACT_147108].   Adverse events judged to be potentially 
immune-related should be described on the appropriate eCRF (recommended diagnostic 
algorithms are provided in the Study Procedures Manual). 
Adverse events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorized representative).  The investigator and any 
qu
alified designees are responsible for detecting, documenting, and recording events that meet 
the definition of an AE or SAE and remain responsible for following-up on AEs that are serious, 
considered related to the study drug/procedures, or that caused the participant to discontinue the 
study drug.  Care will be taken not to introduce bias when detecting AEs and/or SAEs.  
Open-ended and nonleading verbal questioning of the participant, such as "How are you 
feeling?" is the preferred method to inquire about AE occurrences.  Adverse events may also be 
de
tected when they are volunteered by [CONTACT_352949], or through physical examinations, laboratory tests, or other assessments.  The definition, 
reporting, and recording requirements for AEs are described in Section 9. 
All SAEs will be recorded and reported to the sponsor or designee within 24 hours.  The 
investigator will submit any updated SAE data to the sponsor within 24 hours of it being 
available. 
After the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs, and nonserious AEs of special interest (as defined in 
Section 9.5), will be followed until resolution, stabilization, the event is otherwise explained, or 
the participant is lost to follow-up (as defined in Section 7.3). 
The severity of adverse events will be determined per CTCAE v5.0. 

Incyte Corporation Page [ADDRESS_737914] be performed by a medically qualified individual, such as a licensed 
physician, physician's assistant, or an advanced registered nurse practitioner, as local law 
permits.  Abnormalities identified after the first dose of study drug constitute an AE if they are 
considered clinically meaningful, induce clinical signs or symptoms, require concomitant 
therapy, or require changes in study drug (with the exception of abnormalities associated with 
disease progression).  Investigators should pay special attention to clinical signs related to 
previous serious illnesses. 
At the screening visit and EOT, a comprehensive physical examination should be conducted.  
The comprehensive physical examination will include height and body weight and assessment o f 
the following organ or body systems:  skin; head, eyes, ears, nose, and throat; thyroid; lungs; 
cardiovascular system; abdomen (liver, spleen); extremities; and lymph nodes; as well as a brief 
neurological examination. 
During the study, participants will be assessed by [CONTACT_89199].  These assessments should be an evaluation as 
indicated by [CONTACT_89200], AEs, or other findings and documented on the AE eCRF.   
Weight will also be assessed at each study visit. 
In addition, a disease-related clinical assessment should be performed at each study visit. 
8.3.3.  V
ital Signs 
Vital sign measurements (to be taken before blood collection for laboratory tests) include blood 
pressure, pulse, respi[INVESTIGATOR_697], and body temperature.  Blood pressure and pulse will be taken 
with the participant in the recumbent, semirecumbent, or sitting position after [ADDRESS_737915] dose of study drug constitute an AE if they 
are considered clinically meaningful, induce clinical signs or symptoms, require concomitant 
therapy, or require changes in study drug. 
8.3.4.  ECOG Performance Status 
ECOG performance status will be assessed according to the criteria in Table 19 . 
T
able 19: ECOG Performance Status 
Grade  Performance Status  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenu ous activity but ambulatory and able to carry out work of a light or 
sedentary nature, eg, light house work, office work.  
2 Ambulatory and capable of all self -care but unable to carry out any work activities.  Up and abou t more 
than 50% of waking hours.  
3 Capable of only limited self -care, confined to bed or chair more than 50% of waking hou rs. 
4 Completely disabled.  Cannot carry on any self -care.  T otally confined to bed or chair.  
5 Dead . 
Source:  Oken  et al [ADDRESS_737916]. 
The 12-lead ECGs will be interpreted by [CONTACT_561530].  Additional 12-lead ECGs may be performed as clinically indicated to 
m
anage participant safety.  The decision to include or exclude a participant or withdraw a 
pa
rticipant from the study drug based on an ECG flagged as "Abnormal, Clinically Significant" 
is the responsibility of the investigator, in consultation with the sponsor's medical monitor, as 
appropriate.  Clinically notable abnormalities that are considered clinically significant in the 
j
udgment of the investigator are to be reported as AEs. 
8.3.6.  Laboratory Assessments 
Clinical safety laboratory analyses ( ie, blood chemistries, hematology assessments, coagulation 
tests, endocrine function, lipid panel [fasting], and urinalysis) will be performed in certified local 
l
aboratories associated with study sites.  Blood and urine samples will be collected for laboratory 
a
nalyses during study visits, before study treatment administration, according to the schedule in 
Table 3.  The laboratory analytes to be evaluated are presented in T able 20 .  Additional testing 
may be required by [CONTACT_89202].  Additional tests may also be 
performed if clinically indicated. 
Analysis by [CONTACT_89203]–related decisions are acceptable using a 
c
ertified laboratory available to the investigative site.  The investigative site will enter the results 
and normal ranges into the eCRF from any local laboratory analysis. 
Further detailed information regarding collection, processing, and shippi[INVESTIGATOR_89154]. 
Clinically significant abnormal laboratory findings are those that are not associated with the 
underlying disease, unless judged by [CONTACT_41411]'s condition.  All abnormal laboratory values considered clinically significant up to 
[ADDRESS_737917] be repeated before the 
initial study treatment administration on Cycle 1 Day 1.  After Cycle 1, predose laboratory 
procedures can be conducted up to 72 hours before study treatment administration, and results 
should be reviewed by [CONTACT_89204] a 
new cycle of treatment is initiated. 
Incyte Corporation Page 50 of 84 
P
rotocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL A final laboratory analysis is required during the 28-day follow-up safety visit.  These laboratory 
assessments should only be performed at the EOT visit if the EOT visit is also serving as the 
28-day safety visit. 
 
  
 
 
[IP_ADDRESS].  P
regnancy Testing 
Serum pregnancy tests are required for all women of childbearing potential during screening and 
either EOT or the safety follow-up visit [ADDRESS_737918] is performed during screening within 
7 days of Cycle 1 Day 1, it is not necessary to repeat on Cycle 1 Day 1 (unless necessary based 
on
 country-specific requirements). 
A positive urine pregnancy should be confirmed with a serum pregnancy test.  If a pregnancy is 
confirmed by a serum pregnancy test, see Section 9.7. 
T
iming and type of pregnancy testing may be adjusted based on country-specific requirements. 

Incyte Corporation  Page 51 of 84 
Protocol INCMGA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Table 20: Required Laboratory Analytes 
Blood Chemistries  Hematology  Urinalysis With 
Microscopic Examination  Coagulation  Pregnancy Testing  
Albumin  
Alkaline phosphatase  
ALT 
AST 
Amylase  
Bicarbonate or CO 2a 
Blood urea nitrogen or ureaa 
Calcium  
Chloride  
Creatinine  
Glucose  
Lactate dehydrogenase  
Lipase  
Phosphate  
Potassium  
Sodium  
Total bilirubin  
Direct bilirubin (if total bilirubin 
is elevated above ULN)  
Total protein  
Uric acid  Complete blood count, 
includi ng: 
 Hemoglobin  
 Hematocrit  
 Platelet count  
 Red blood cell count  
 WBC count  
 
Differential count, including:  
 Basophils  
 Eosinophils  
 Lymphocytes  
 Monocytes  
 Neutrophils  
 
Absolute values must be 
provided for:  
 WBC differential 
laboratory results  Color and appearance  
pH and specific gravity  
Bilirubin  
Glucose  
Ketones  
Leukocytes  
Nitrite  
Occult blood  
Protein  PT 
PTT or aPTT  
INR Women of childbearing 
potential  
Lipid Panel  (Fasting)  Endocrine Function  HIV Management Testingb 
(Only participants who are 
known to be HIV -positive)  
Total cholesterol  
Triglycerides  
LDL  
HDL  TSH 
T4 
T3/FT3a  
 
a If considered standard by [CONTACT_561531]. 
  
Note:  Additional tests may be required, as agreed by [CONTACT_147100], based on emerging safety data. 

Incyte Corporation Page [ADDRESS_737919] dates and times of the PK blood collection will be recorded in the 
eCRF.  Instructions for sample preparation and shippi[INVESTIGATOR_561514]. 
8.5. Pharmacodynamic  Assessments 
8.5.2.  Tissue Biopsies  
Tumor tissue should be collected during screening (fresh or archival tissue) according to the 
s
chedule outlined in Table 4.  Detailed information regarding procedures for handling and 
s
hippi[INVESTIGATOR_561515] a separate laboratory manual. 
 
 

Incyte Corporation Page 53 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 8.5.3.  Blood Sample Collection 
Whole blood, serum, and plasma will be collected according to the schedule outlined in Table 4 .  
D
etailed information regarding procedures for handling and shippi[INVESTIGATOR_561516] a separate laboratory manual. 
 
 
8.6. Unsch
eduled Visits 
Unscheduled study visits may occur at any time if medically warranted.  Any assessments 
performed at those visits should be recorded in the eCRF. 
8.7. End of Treatment and/or Early Termination 
Once a participant permanently discontinues study treatment, the EOT visit should be conducted, 
and the data should be entered in the EOT visit in the eCRF.  If the EOT visit coincides with a 
regular study visit, the EOT evaluations will supersede those of that scheduled visit.  Should 
study treatment discontinuation occur < 21 days after the final dose of study treatment, a 28-day 
safety follow-up visit is required and should be conducted according to Table 3  and T able 4.  If 
t
he EOT visit occurs ≥ [ADDRESS_737920] study treatment, only a single EOT/28-day safety 
follow up is required; otherwise, the EOT visit will also serve as the 28-day safety follow-up 
visit, and the EOT assessment schedule will be followed. 
 
8
.8. Foll
ow-Up 
The study design includes a follow-up period for participants subsequent to the end of the study 
treatment period.  After discontinuation of study treatment, all study participants continue in the 
follow-up period of the study as described in Table 3 .  
 
 
8.8.1.  Safety Fol
low-Up 
The safety follow-up period starts once the participant discontinues study treatment.  
Approximately 28 days after the final dose of study drug (± 7 days), participants are to attend a 
clinical visit for a safety evaluation.  During this visit, blood will be collected for safety 
laboratory analysis, a physical exam will be performed, and AEs and concomitant medications 
will be assessed according to the scheduled assessments found in Table 3.  Participants will be 
f
ollowed for irAEs for [ADDRESS_737921]-Treatment Disease Follow- Up 
Participants who discontinue study drug for a reason other than disease progression will move 
into the disease status follow-up period and should be assessed every 12 weeks ± [ADDRESS_737922] information 
regarding disease status until: 
 The start of new anticancer therapy. 
 Disease progression. 
 Death. 
 The end of the study. 
 Participant is lost to follow-up. 
8.8.3.  Survival Follow- Up 
Once a participant has received the last dose of study drug, has confirmed disease progression, or 
starts a new anticancer therapy, the participant moves into the survival follow-up period and 
should be contact[CONTACT_5143], email, or visit at least every [ADDRESS_737923]. 
For participants having entered the survival follow-up period of the study, the site will use 
continuing participant records to supply data on subsequent treatment regimens, tumor 
assessments (if discontinued treatment for a reason other than progression), and OS in the eCRF.  
F
or participants who do not intend to return to the study investigator for their ongoing care, 
follow-up should be maintained by [CONTACT_89205], patient records, and public records/databases 
at intervals of no longer than 12 weeks. 
Incyte Corporation Page 55 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 9. ADVERSE EVENTS:  DEFINITIONS AND PROCEDURES FOR 
RECORDING, EVALUATING, FOLLOW-UP, AND REPORTING 
9.1. Definition of Adverse Event 
Adverse Event Definition  
 An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not 
considered drug -related.  
 An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory 
finding), symptom, or disease (new or exacerbated) temporally associated with the  use of study drug . 
Events Meeting  the A dverse Event Definition  
 Any safety assessments ( eg, ECG, vital signs measurements), including those that worsen from 
baseline, considered clinically significant in the medical and scientific judgment of the invest igator 
(ie, not related to progression of underlying disease).  
 Abnormal  laboratory test results constitute an AE if they are considered clinically meaningful, induce 
clinical signs or symptoms, require concomitant therapy, or require changes in study drug.   Whenever 
possible, a diagnosis ( eg, anemia, thrombocytopenia) should be recorded in the eCRF rather than the 
abnormal lab result ( eg, low hemoglobin, platelet count decreased).  
 Exacerbation of a chronic or intermittent pre -existing condition including ei ther an increase in 
frequency and/or intensity of the condition.  
 New conditions detected or diagnosed after study drug  administration even though they may have been 
present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspe cted drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug  or a concomitant 
medication .  Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose 
taken with possible suic idal/self -harming intent .  Such overdoses should be reported regardless of 
sequelae.  
Events NOT  Meeting the A dverse Event Definition  
 Any clinically significant abnormal laboratory findings or other abnormal safety assessments that are 
associated with the  underlying disease, unless judged by [CONTACT_19988] 's condition.  
 The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder 
being studied, unless more severe  than expected for the participant 's condition  or considered to be 
treatment -related by [CONTACT_093] . 
 Efficacy endpoints as outlined in Section  3 will not be reported as AE/SAEs, specifically, any event 
that is related to disease progression of the cancer under study.  Unblinded aggregated efficacy endpoint 
events and safety data will be monitored to ensure the safety of the participant s in the study .  Any 
suspected endpoint that upon review is not progression  of the cancer under study will be forwarded to 
Incyte Pharmacovigilance as a SAE within 24 hours of determination that the event is not progression 
of the cancer under study.  
 Medical or surgical procedure ( eg, endoscopy, appendectomy):  the condition that  leads to the 
procedure is the AE  if it occurred after signing informed consent .  If present before entering the study, 
the condition  should be captured as medical history.  
 Situations in which an untoward medical occurrence did not occur (social and/or con venience 
admission to a hospi[INVESTIGATOR_307]).  
 Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at the 
start of the study that do not worsen.  
Incyte Corporation Page 56 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 9.2. Definition of Serious Adverse Event 
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions 
are met ( eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to 
pr
ogression of disease). 
A Serious Adverse Event is defined as any untoward medical occurrence that, at any  dose:  
a.  Results in death  
b.  Is life -threatening  
The term 'life-threatening ' in the definition of 'serious ' refers to an adverse drug experience that places the 
participant , in the opi[INVESTIGATOR_89155], at immediate risk of death from the adverse  experience as 
it occurred.  This does not include an adverse drug experience that, had it occurred in a more severe form, 
might have caused death . 
c.  Requires inpatient hospi[INVESTIGATOR_12993], hospi[INVESTIGATOR_561517] (usually involving at least an 
overnight stay) at the hospi[INVESTIGATOR_9235]/or treatment that would not have 
been appropriate in the physician 's office or outpatient setting .  Compl ications that occur during 
hospi[INVESTIGATOR_1084] .  If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious .  When in doubt as to whether "hospi[INVESTIGATOR_059] " occurred or was necessary, the AE 
should be conside red serious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen from baseline is not 
considered an AE.  
d.  Results in persistent or significant disability/incapacity  
 The term disability means a substantial disruption of a person 's ability to conduct normal life functions.  
 This definition is not intended to include experiences of relatively minor medical significance , such as 
uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma ( eg, sprained 
ankle) , that may interfere with or prevent everyday life functions but do not constitute a substantial 
disruption.  
e.  Is a congenital anomaly/birth defect  
f. Other situations  (Important Medical Event)  
An event that may not result in death, be immediately life -threatening, or require hospi[INVESTIGATOR_059], but may 
be considered serious when, based on appropriate medical judgment, the event may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes listed in the 
above  definition.   Examples of such events include invasive or malignant cancers  (excluding the 
disease[s] under study in oncology protocols) , intensive treatment in an emergency department  or at home 
for allergic bronchospasm, blood dyscrasias , or convulsions that do not result in hospi[INVESTIGATOR_059], or 
development of drug dependency or drug abuse.  
Incyte Corporation Page 57 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 9.3. Recording and Follow-Up of Adverse Events and/or Serious Adverse 
Events 
Adverse Event and S erious Adverse Event Recording  
 An AE/SAE that begins or worsens after infor med consent is signed should be recorded on the Adverse 
Event  Form in the eCRF .  Conditions that were present at the time informed consent was given should 
be recorded on the Medical History Form in the eCRF.  
 When an AE/SAE occurs, it is the responsibility  of the investigator to review all documentation 
(eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
 The investigator (or delegate) will then record all relevant AE/SAE information in the eCRF.  
 It is not accepta ble for the investigator to send photocopi[INVESTIGATOR_10914] 's medical records in lieu 
of completing  the AE eCRF page.  
 There may be instances when copi[INVESTIGATOR_63475] .  In this case, all 
participant identifiers, wit h the exception of the participant number, will be redacted on the copi[INVESTIGATOR_346590].  
 The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or 
other clinical information .  Whenever p ossible, the diagnosis (not the individual signs/symptoms) will 
be documented as the AE/SAE .  When a clear diagnosis cannot be identified, each sign or symptom 
should be reported as a separate AE /SAE . 
To the extent possible, each AE /SAE  should be evaluated  to determine:  
 The severity grade (CTCAE Grade 1 to 5).  See below for further instructions on the assessment of 
intensity.  
 Whether there is at least a reasonable possibility that the AE is related to the study drug :  suspected 
(yes) or not suspected (no) .  See below for further instructions on the assessment of causality.  
 The start and end dates, unless unresolved at final follow -up. 
 The action taken with regard to each study drug  as a result of the AE/SAE (s). 
 The event outcome ( eg, not recovered/not resol ved, recovered/resolved, recovering/resolving, 
recovered/resolved with sequelae, fatal, unknown).  
 The seriousness, as per the SAE definition provided in Section  9.2. 
 The action taken with regard to the event .  Note:  If an AE is treated with a concomitant medication or 
nondrug therapy, this action should be recorded on Adverse Event Form and the treatment should be 
specified on the appropriate eCRF ( eg, Prior/Concomitant Medications , Procedures and Non -Drug 
Therap y). 
Assessment of Intensity  
The severity of AEs will be assessed using CTCAE v5.0 Grades 1 through 5 .  If an event is not classified 
by [CONTACT_3989], the severity of the AE will be graded according to the scale below to estimate the grade of 
severity:  
The inves tigator will make an assessment of intensity for each AE and SAE reported during the study and 
assign it to 1 of the following categories:  
 Grade 1:   Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; treatment  
not indicated.  
 Grade 2:   Moderate; minimal, local, or noninvasive treatment  indicated; limiting age appropriate 
activities of daily living.  
 Grade 3:   Severe or medical significant but not immediately life -threatening; hospi[INVESTIGATOR_561518]; disabling; limiting self -care activities of daily living.  
 Grade 4:   Life-threatening consequences; urgent treatment  indicated.  
 Grade 5:   Fatal.  
Incyte Corporation Page 58 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Assessment of Causality  
 The investigator is obligated to assess the relationship between each study drug and each occurrence of 
each AE/SAE . 
 A "reasonable possibility " of a relationship conveys that there are facts, evidence, and/or arguments to 
suggest a causal relationship, rather than that a relationship cannot be ruled out.  
 The investigator will use clin ical judgment to determine the relationship.  
 The investigator will also consult the Reference Safety Information  in the IB and/or Product 
Information, for marketed products, in his/her assessment.  
 Alternative causes, such as underlying disease(s), concomit ant therapy, and other risk factors, as well as 
the temporal relationship of the event to study drug  administration , will be considered and investigated.  
 For each AE/SAE, the investigator must  document in the medical notes that he/she has reviewed the 
AE/S AE and has provided an assessment of causality.  
 With regard to assessing causality of SAEs:  
 There may be situations in which an SAE has occurred and the investigator has minimal information 
to include in the initial report .  However,  the causality assessme nt is one of the criteria used when 
determining regulatory reporting requirements.  Therefore,  it is very important that the 
investigator always make an assessment of causality for every event before the initial 
transmission of the SAE.  
 The investigator ma y change his/her opi[INVESTIGATOR_9242] -up information and send a 
follow -up SAE report with the updated causality assessment.  
Follow -Up of A dverse Events and S erious Adverse Events 
 The investigator is obligated to perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_22854]/or 
causality of the AE or SAE as fully as possible .  This may include additional laboratory tests or 
investigation s, histopathological examinations, or consultation with other health care professionals.  
 New or updated information will be recorded in the originally completed eCRF.  
 Any updated SAE data will be submit ted to the sponsor (or designee) within 24  hours of re ceipt of the 
information.  
 Once an AE is detected, it should be followed until it has resolved or until it is judged to be permanent; 
assessment should be made at each visit (or more frequently if necessary) of any changes in severity, 
the suspected relatio nship to the study drug, the interventions required to treat the event, and the 
outcome.  
 When the severity of an AE changes over time for a reporting period ( eg, between visits), each change 
in severity will be reported as a separate AE until the event res olves . 
9.4. Reporting of Serious Adverse Events 
Regardless of suspected causality ( eg, relationship to study drug or study procedure s), all SAEs 
occurring after the participant has signed the ICF through [ADDRESS_737924] be reported to the sponsor 
(
or designee) within [ADDRESS_737925]
ug.  The investigator will submit any updated SAE data to the sponsor (or designee) within 
24 hours of it being available.  
Incyte Corporation Page 59 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Investigators are not obligated to actively seek AE or SAE information after conclusion of the 
study participation.  However, if the investigator learns of any SAE, including a death, at any 
t
ime after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study drug or study participation, the investigator must notify the 
sponsor (or designee) within 24 hours of becoming aware of the event. 
A
fter the initial AE/SAE report, the investigator is required to proactively follow each participant 
at subsequent visits/contacts.  All SAEs, [and nonserious AEs of special interest (as defined in 
Section 9.5), will be followed until resolution, stabilization, the event is otherwise explained, or 
t
he participant is lost to follow-up (as defined in Section 7.3). 
Prompt notification by [CONTACT_11012] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
drug under clinical investigation are met. 
I
f the SAE is not documented in the IB for the study drug (new occurrence) and is thought to be 
related to the sponsor's study drug, the sponsor or its designee may urgently require further 
information from the investigator for reporting to health authorities.  The sponsor or its designee 
may need to issue an Investigator Notification to inform all investigators involved in any study 
with the same drug that this SAE has been reported.  S[LOCATION_003]Rs will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with Directive 
2001/20/EC, or as per national regulatory requirements in participating countries. 
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study drug under clinical investigation.  The sponsor 
will comply with country-specific regulatory requirements relating to safety reporting to the 
regulatory authority, IRB/IEC, and investigators. 
Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local regulatory 
requirements and sponsor policy and forwarded to investigators as necessary. 
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information ( eg, summary or listing of SAEs) from the sponsor will review and then file it 
a
long with the IB and will notify the IRB/IEC, if appropriate according to local requirements. 
Incyte Corporation Page 60 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Serious Adverse Event Reporting  
 Information about all SAEs is c ollected and recorded on the Adverse Event Form in the eCRF . 
 The investigator must also complete the Incyte Serious Adverse Event Report Form, in English .  Refer 
to the Incyte Reference Guide for Completing the Serious Adverse Event Report Form.  
 Facsimile or email transmission of the Serious Adverse Event  Report Form  is the preferred method to 
transmit this information to PhV/designee .  The contact [CONTACT_89208] 's study -specific 
representatives is l isted in the Study Procedures Manual  provided to each site .  The original copy of the 
Serious Adverse Event  Report Form and the confirmation sheet must be kept at the study site.  
 Follow -up information is recorded on an amended or new Serious Adverse Event  Report Form, with an 
indication that it is fol low-up to the previously reported SAE and the date of the original report .  The 
follow -up report should include information that was not provided on the previous Serious Adverse 
Event  Report Form, such as the outcome of the event ( eg, resolved or ongoing),  treatment provided, 
action taken with each study drug because of the SAE ( eg, dose reduced, interrupted, or discontinued), 
or participant  disposition ( eg, continued or withdrew from study participation) .  Each recurrence, 
complication, or progression of t he original event should be reported as follow -up to that event, 
regardless of when it occurs.  
 In rare circumstances and in the absence of facsimile or computer equipment, notification by [CONTACT_13186] a copy of the Incyte Serious Adverse Ev ent Report Form  sent by [CONTACT_20022] .  Initial notification via telephone does not replace the need for the investigator to 
complete and sign the Serious Adverse Event  Report Form  within the designated reporting time frames.  
 Contacts f or SAE reporting can be found in the Study Procedures Manual . 
9.5. Adverse Events of Special Interest 
Not applicable. 
9.6. Emergency Unblinding of Treatment Assignment 
Not applicable. 
9.7. Pregnancy 
Pregnancy, in and of itself, is not regarded as an AE unless there is suspi[INVESTIGATOR_147066] a contraceptive medication or method.  When a 
pregnancy has been confirmed in a participant during maternal or paternal exposure to study 
drug, the following procedures should be followed in order to ensure safety: 
 The study drug must be interrupted immediately (female participants only). 
 If the female participant is no longer pregnant and meets the treatment continuation 
criteria within 12 weeks of the scheduled start of a cycle, study drug may be resumed 
after approval has been received from the sponsor medical monitor. 
 The investigator must complete and submit the Incyte Clinical Trial Pregnancy Form 
to the sponsor or its designee within 24 hours  of learning of the pregnancy. 
Incyte Corporation Page 61 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Data on fetal outcome are collected for regulatory reporting and drug safety evaluation.  
Follow-up should be conducted for each pregnancy to determine outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any birth defects, 
congenital abnormalities, or maternal and/or newborn complications, by [CONTACT_89210]-baby [CONTACT_765].  Pregnancy should be recorded on a Clinical Trial Pregnancy Form and reported 
by
 [CONTACT_427464].  Pregnancy follow-up information should be 
r
ecorded on the same form and should include an assessment of the possible causal relationship 
to the sponsor's study drug to any pregnancy outcome, as well as follow-up to the first well-baby 
[CONTACT_89212], whichever is later.  Refer to the Incyte 
R
eference Guide for Completing the Clinical Trial Pregnancy Form. 
Any SAE occurring during pregnancy of a study participant must be recorded on the 
Serious Adverse Event Report Form and submitted to the sponsor or designee. 
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, or ectopic pregnancy) are considered SAEs (if occurring in the study participant) and 
must be reported as described in Section 9.4.  If an abnormal pregnancy outcome is reported in a 
s
tudy participant's partner, the event should be reported to the sponsor on the Clinical Trial 
Pregnancy Form. 
9.8. Warnings and Precautions 
Special warnings or precautions for study drug, derived from safety information collected by [CONTACT_117561], are presented in the IB.  Additional safety information collected between 
IB updates will be communicated in the form of Investigator Notifications.  Any important new 
safety information should be discussed with the participant during the study, as necessary.  If 
new significant risks are identified, they will be added to the ICF. 
9.9. Product Complaints 
The sponsor collects product complaints on study drug and drug delivery systems used in clinical 
studies in order to ensure the safety of study participants, monitor quality, and facilitate process 
and product improvements. 
All product complaints associated with material packaged, labeled, and released by [CONTACT_319862].  All product complaints associated with other 
study material will be reported directly to the respective manufacturer. 
The investigator or his/her designee is responsible for reporting a complete description of the 
product complaint via email or other written communication to the sponsor contact [CONTACT_147111].  Any AE associated with a product 
complaint should be recorded as described in Section 9.3. 
I
f the investigator is asked to return the product for investigation, he/she will return a copy of the 
product complaint communication with the product. 
Incyte Corporation Page 62 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 10. STATISTICS 
10.1. Sample Size Determination 
In a recent single-arm Phase 2 study, nivolumab achieved an ORR of 24% in participants with 
unresectable metastatic anal cancer ( Morris et al 2017 ). 
Based on a target ORR of 25% and a sample size of 81, the study has 80% power to exclude a 
lower confidence limit of 13% with alpha equal to 0.025 (1-sided).   T he sample size calculation 
is based on participants’ full analysis set defined in the next section. 
10.2. Populations for Analysis 
Table 21 presents the populations for analysis. 
T
able 21: Populations for Analysis 
Population  Description  
Full analysis set  The FAS includes all participants enrolled in the study who received at least [ADDRESS_737926] 1  postdose serum  sample (1 PK 
measurement).  
 
 
  
 
 
10.3. Level of Significance 
There is no formal hypothesis testing in this study.  Response rate as well as the associated 
95%
 CI will be provided. 
1
0.4. Statistical Analyses 
The Statistical Analysis Plan will be developed and finalized before database lock and will 
describe the participant populations to be included in the analyses and procedures for accounting 
for missing, unused, and spurious data.  This section is a summary of the planned statistical 
analyses of the primary and secondary endpoints. 

Incyte Corporation Page 63 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 10.4.1.  Primary Analysis 
[IP_ADDRESS].  Overall Response Rate 
The primary endpoint of the study is ORR, defined as the percentage of participants with CR or 
PR, according to RECIST v1.1 ( Eisenhauer et al 2009 ) as determined by [CONTACT_89215].  The primary 
analysis of ORR will be based on the FAS.  Objective response rate and its exact 95% CI  will be 
presented. 
[IP_ADDRESS].  Handling of Missing Data in Primary Analysis 
Complete response or PR reported before any additional anticancer therapy will be considered a s 
r
esponse in the calculation of ORR irrespective of the number of missed assessments before 
response. 
10.4.2.  Secondary Analysis 
[IP_ADDRESS].  Duration of Response 
Duration of response is defined as the time from first documented response (CR or PR) to the 
time of first documented disease progression or death due to any cause.  If a participant does not 
h
ave an event before data cutoff or new anticancer therapy, DOR is censored at the date of the 
last adequate tumor assessment before data cut off or new anticancer therapy.  The Kaplan-Meier 
estimate of the distribution function will be constructed for DOR.  The estimated median along 
with 95% CIs will be reported. 
[IP_ADDRESS].  Disease Control Rate 
Disease control rate defined as the proportion of participants with an overall response ( CR and 
PR), or stable disease per RECIST v1.1, according the ICR.   T he DCR will be estimated, and the 
exact 95% CI will be reported. 
[IP_ADDRESS].  Progression-Free Survival 
Progression-free survival, defined as the time from the first dose of study treatment to the date of 
the
 first documented progression per RECIST v1.1 or death due to any cause.  Progression-free 
s
urvival data will be analyzed by [CONTACT_8761]-Meier method, including estimated median with 
95% CI and Kaplan-Meier estimated probabilities at several timepoints.  I f pa rticipants have no 
observed death or disease progression before data cutoff or new anticancer therapy, the 
pa
rticipants will be treated as censored at their last adequate tumor assessment before cutoff or 
n
ew anticancer therapy. 
[IP_ADDRESS].  Overall Survival 
Overall survival is defined as the time from first dose of study treatment to the date of death due 
to any cause.  Participants still alive at the time of analysis will be censored at the date of last 
known alive.  Kaplan-Meier curves, medians, and 95% CIs  of the medians will be presented. 
Incyte Corporation Page 64 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 10.4.3.  Safety Analyses 
[IP_ADDRESS].  Adverse Events 
Safety analyses will be conducted for the safety population.  Adverse events will be coded by [CONTACT_252740], and TEAEs ( ie, AEs reported for the first time or worsening of a 
pre-existing event after first dose of study drug) will be tabulated by [CONTACT_561532], related events, and events of Grade 3 or higher. 
[IP_ADDRESS].  Adverse Events of Special Interest 
Adverse events of special interest will include irAEs. 
[IP_ADDRESS].  Clinical Laboratory Tests 
The clinical laboratory data will be analyzed using summary statistics.  In addition, distributions 
of key laboratory parameters may be plotted over time; these values will also be classified into 
CTCAE toxicity grades and tabulated. 
Laboratory test values outside the normal range will be assessed for severity based on the normal 
ranges for the clinical reference laboratory.  The incidence of abnormal laboratory values and 
s
hift tables relative to baseline will be tabulated.  The following summaries will be produced for 
t
he laboratory data: 
 Number and percentage of participants with worst postbaseline CTCAE grade 
(regardless of baseline value).  Each participant will be counted only for the wors t 
g
rade observed postbaseline. 
 Shift tables from baseline to the worst postbaseline value using CTCAE grade. 
 For laboratory parameters where CTCAE grades are not defined, shift tables to the 
worst postbaseline value using the low/normal/high classifications based on 
laboratory reference ranges. 
[IP_ADDRESS].  Vital Signs 
Descriptive statistics and mean change from baseline will be determined for vital signs (blood 
pressure, pulse, respi[INVESTIGATOR_697], and body temperature) at each assessment time.  Vital sign 
r
esults will be reviewed for clinically notable abnormalities, and participants exhibiting clinically 
notable vital sign abnormalities will be listed. 
[IP_ADDRESS].  Electrocardiograms 
Descriptive statistics and mean change from baseline will be determined for each ECG parameter 
at each assessment time.  Electrocardiogram results will be reviewed for clinically notable 
abnormalities according to predefined criteria as described in the Statistical Analysis Plan. 
[IP_ADDRESS].  Dose Intensity 
Measures of exposure (eg, days of exposure, dose intensity, etc) of study drug will be 
summarized by [CONTACT_63408]. 
Incyte Corporation Page [ADDRESS_737927] population PK methods using appropriate software ( eg, NONMEM).  Otherwise, the data 
will be pooled with data from other studies for a population PK analysis.  

Incyte Corporation Page [ADDRESS_737928] v1.1.  The primary intent of this analysis is to minimize unnecessary exposure of 
participants to INCMGA00012 in the event of futility.  The study will be stopped for futility at 
the interim analysis if conditional power based on interim result is lower than 20%, which is 
equivalent to less than 2 participants responded.  All participants enrolled with a postbaseline 
r
esponse assessment or participants early discontinued will be included in the futility analysis.  
Participants enrolled in the study without any postbaseline response assessment but are ongoing 
i
n the study will not be included in the futility analysis for calculation of conditional power.  
Enrollment will continue while the analysis is being conducted.  This futility analysis will be 
reviewed by [CONTACT_561533].  The process by [CONTACT_561534].  The Statistical Analysis Plan will describe the planned interim analyses in greater 
de
tail. 
  
 
 

Incyte Corporation Page 67 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 11. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS 
11.1. Investigator Responsibilities 
 The Protocol, Protocol amendments, ICF, IB, and other relevant documents 
(eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_31846]/IEC before the study is initiated. 
 The investigator is responsible for ensuring that the safety reports provided by [CONTACT_89222], the 
pol
icies and procedures established by [CONTACT_1201]/IEC, and institutional requirements. 
 A
ny amendments to the Protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants. 
 The investigator will be responsible for the following: 
 Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC. 
 N
otifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures. 
 Providing oversight of the conduct of the study at the site and adherence to GCP, 
IRB/IEC requirements, institutional requirements, and applicable laws and 
country-specific regulations.  
 Adhering to the Protocol as described in this document and agreeing that changes to 
the Protocol procedures, with the exception of medical emergencies, must be 
discussed and approved, first, by [CONTACT_89223], second, by [CONTACT_5040]/IEC.  Each investigator is responsible for enrolling participants who have met 
the specified eligibility criteria. 
 Retaining records in accordance with all local, national, and regulatory laws, but for a 
minimum period of at least [ADDRESS_737929] article for 
i
nvestigation to ensure the availability of study documentation should it become 
necessary for the sponsor or a regulatory authority to review. 
 The investigator must not destroy any records associated with the study without 
receiving approval from the sponsor.  The investigator must notify the sponsor or 
its designee in the event of accidental loss or destruction of any study records.  If 
the investigator leaves the institution where the study was conducted, the sponsor 
or its designee must be contact[CONTACT_89224]. 
 All eCRF data entered by [CONTACT_779] (including audit trail), as well as computer 
hardware and software (for accessing the data), will be maintained or made 
available at the site in compliance with applicable record retention regulations.  
The sponsor will retain the original eCRF data and audit trail. 
Incyte Corporation Page 68 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 11.2. Data Management 
Data management will be performed in a validated EDC system.  The investigator will be 
provided with access to an EDC system so that an eCRF can be completed for each participant. 
The site will be provided eCRF completion guidelines for instructions on data entry in the eCRF.  
The study monitor will reference the Monitoring Plan in order to ensure that each issue identified 
is appropriately documented, reported, and resolved in a timely manner in accordance with the 
plan's requirements.   Other data outside the EDC system required in the study conduct of the 
protocol such as documents or results transmitted to the sponsor via a central laboratory or 
specialized technical vendors, and as designated by [CONTACT_456], will have their own data flow 
management plans, or study charters,  as applicable. 
The sponsor (or designee) will be responsible for: 
 Managing the integrity of the data and the quality of the conduct of the study, such as 
ensuring that study monitors perform ongoing source data verification to confirm that 
data entered into the eCRF by [CONTACT_1191], complete, and 
verifiable from source documents; that the safety and rights of participants are being 
protected; and that the study is being conducted in accordance with the currently 
approved protocol and any other study agreements, ICH GCP, and all applicable 
regulatory requirements. 
 Managing and reconciling the data generated, and/or collected including documents 
and results such as laboratory or imaging data analyzed centrally by a designated 
vendor of the sponsor. 
The investigator will be responsible for: 
 Recording, or ensuring the recording of, all relevant data relating to the study in the 
eCRF. 
 Delivering, or ensuring the delivery of, all other results, documents, data, know-how, 
or formulas relating to the study to the sponsor or designee electronically and/or 
centrally (eg, laboratory data, imaging data, , photographs, diary data), 
or as otherwise specified in the Protocol. 
 Verifying that data entries are accurate and correct by [CONTACT_108125]. 
 Maintaining accurate documentation (source data) that supports the information 
entered in the eCRF, or sent to a central vendor designated by [CONTACT_456], or as 
described in other study and data flow manuals. 
 Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected.  Source documents are filed at the 
investigator's site. 
 Data entered in the eCRF that are transcribed from source documents must be 
consistent with the source documents or the discrepancies must be explained.  The 
investigator may need to request previous medical records or transfer records, 
depending on the study.  Also, current applicable medical records must be 
available. 

Incyte Corporation Page 69 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL  May have responsibility for sending participants' data, either as unique samples, or 
c
opi[INVESTIGATOR_014], or photographs, to be evaluated centrally or analyzed centrally, or both, by a 
qualified vendor designated by [CONTACT_456].  
 Permitting study-related monitoring, sponsor audits, IRB/IEC review, and regulatory 
inspections by [CONTACT_89225]. 
 Monitoring:  Qualified representatives of the sponsor or its designee, study 
monitors, will monitor the study according to a predetermined plan.  The 
investigator must allow the study monitors to review any study materials and 
participant records at each monitoring visit. 
 Auditing:  Qualified representatives of the sponsor or its designee may audit the 
clinical study site and study data to evaluate compliance with the Protocol, 
applicable local clinical study regulations, and overall study conduct.  The 
investigator must allow the auditors to review original source records and study 
documentation for all participants. 
 Regulatory inspection:  Regulatory authorities may conduct an inspection of the 
study and the site at any time during the development of an investigational 
product.  The investigator and staff are expected to cooperate with the inspectors 
and allow access to all source documents supporting the eCRFs and other study 
related documents.  The investigator must immediately notify the sponsor when 
contact[CONTACT_147115]. 
11.3. Data Privacy and Confidentiality of Study Records 
The investigator and the sponsor or its designee must adhere to applicable data privacy laws and 
regulations.  The investigator and the sponsor or its designee are responsible for ensuring that 
sensitive information is handled in accordance with local requirements ( eg, HIPAA).  
Appropriate consent and authorizations for use and disclosure and/or transfer (if applicable) of 
protected information must be obtained. 
Participant names will not be supplied to the sponsor or its designee.  Only the participant 
number will be recorded in the eCRF; if the participant's name [CONTACT_75502] 
(eg, laboratory report), it must be obliterated on the copy of the document to be supplied to the 
s
ponsor or its designee.  Study findings stored on a computer will be stored in accordance with 
local data protection laws. 
R
ecords and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_1732] 10  years after study completion unless local regulations or 
institutional policies require a longer retention period.   In the Netherlands, it is mandatory to 
keep the data for 15 years after the end of the research.  No records may be destroyed during the 
retention period without the written approval of the sponsor.  No records may be transferred to 
another location or party without written notification to the sponsor. 
Incyte Corporation Page 70 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 11.4. Financial Disclosure 
Before study initiation, all clinical investigators participating in clinical studies participant to 
F
DA Regulation Title 21 CFR Part 54 – Financial Disclosure by [CONTACT_6230] 
(ie, "covered studies") are required to submit a completed Clinical Investigator Financial 
D
isclosure form that sufficiently details any financial interests and arrangements that apply.  For 
t
he purpose of this regulation, "clinical investigator" is defined as any investigator or 
subinvestigator who is directly involved in the treatment or evaluation of research participants, 
including the spouse and each dependent child of the clinical investigator or subinvestigator.  
These requirements apply to both US and foreign clinical investigators conducting covered 
clinical studies. 
Any new clinical investigators added to the covered clinical study during its conduct must also 
submit a completed Investigator Financial Disclosure Form.  During a covered clinical study, 
any changes to the financial information previously reported by a clinical investigator must be 
reported to the sponsor or its designee.  At the conclusion of the covered clinical study, the 
clinical investigators will be reminded of their obligations.  In the event that the clinical 
investigator is not reminded, they nevertheless will remain obligated to report to the sponsor or 
its designee any changes to the financial information previously reported, as well as any changes 
in their financial information for a period of 1 year after completion of the covered clinical study. 
11.5. Publication Policy 
By [CONTACT_89228], the investigator and his/her institution agree that the results of the 
study may be used by [CONTACT_456], Incyte Corporation (Incyte), for the purposes of national and 
international registration, publication, and information for medical and pharmaceutical 
professionals.  Study results will be published in accordance with applicable local and national 
regulations.  If necessary, the authorities will be notified of the investigator's name, address, 
qualifications, and extent of involvement.  The terms regarding the publication of study results 
are contained in the agreement signed with the sponsor or its designee.  A signed agreement will 
be retained by [CONTACT_3552]. 
The results of this study may be published or presented at scientific meetings.  If this is foreseen, 
the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission.  
This allows the sponsor to protect proprietary information and to provide comments. 
T
he sponsor will comply with the requirements for publication of study results.  In accordance 
with standard editorial and ethical practice, the sponsor will generally support publication of 
multicenter studies only in their entirety and not as individual site data.  In this case, a 
coordinating investigator [INVESTIGATOR_12992]. 
Authorship will be determined in line with International Committee of Medical Journal Editors 
a
uthorship requirements. 
Incyte Corporation Page [ADDRESS_737930] been collected and a study-site closure visit has been performed. 
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination. 
Reasons for the early closure of a study site by [CONTACT_11004]: 
 Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines. 
 I
nadequate recruitment of participants by [CONTACT_093]. 
 D
iscontinuation of further study drug development.  
Incyte Corporation Page 72 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 12. REFERENCES 
Bai S, Jorga K, Xin Y, et al. A guide to rational dosing of monoclonal antibodies. Clin 
Pharmacokinet 2012;51:119-135. 
Brahmer J, Lacchetti C, Schneider B, et al. Management of immune-related adverse events in 
patients treated with immune checkpoint inhibitor therapy: American Society of Clinical 
Oncology Clinical Practice Guideline. J Clin Oncol 2018;36:1714-1768. 
Clinical Trial Facilitation Group. Recommendations related to contraception and pregnancy 
testing in clinical trials. 2014. http://www.hma.eu/fileadmin/dateien/Human_Medicines/ 
01-About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf. 
A
ccessed October 2, 2017. 
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247. 
Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary 
m
anagement in improving the overall survival of patients with metastatic squamous cell 
carcinoma of the anal canal. Oncotarget 2014;5:[ZIP_CODE]-[ZIP_CODE]. 
Freshwater T, Kondic A, Ahamadi M, et al. Evaluation of dosing strategy for pembrolizumab for 
oncology indications. J Immunother Cancer 2017;5:43. 
Ghosn M, Kourie HR, Abdayem P, Antoun J, Nasr D. Anal cancer treatment:  current status and 
future perspectives. World J Gastroenterol 2015;21:2294-2302. 
 
 
I
NCMGA
[ZIP_CODE] Investigator's Brochure. Wilmington, DE: Incyte Corporation. 
Keytruda (pembrolizumab) [prescribing information]. [COMPANY_006] & Co., Inc; November 2017. 
Lakhani N, Mehnert JM, Rasco D, et al. A phase 1 study of the safety, tolerability, and 
pharmacokinetics (PK) of MGA012 (anti- PD-1 antibody) in patients with advanced solid tumors. 
Poster presented at: 32nd Congress of the Society for Immunotherapy of Cancer; 
November 8-12, 2017; National Harbor, MD. Abstract P249. 
M
ehnert J, Joshua A, Lakhani N, et al. First- in-human Phase 1 study of INCMGA00012 in 
patients with advanced solid tumors: interim results of the cohort expansion phase. Abstract 
P669 presented at: The Society for Immunotherapy of Cancer; November 7-11, 2018; 
Washington, DC. 
Morris VK, Salem ME, Nimeiri H, et al. Nivolumab for previously treated unresectable 
metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol 
2017;18:446-453. 
O
ken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655. 
Opdivo (nivolumab) [prescribing information]. Bristol-Myers Squibb Company; April 2018. 

Incyte Corporation Page 73 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Ott PA, Pi[INVESTIGATOR_43154]-Paul SA, Munster P, et al. Safety and antitumor activity of the anti- PD-1 antibody 
pembrolizumab in patients with recurrent carcinoma of the anal canal. Ann Oncol 
2017;28:1036-1041. 
 
 
 
 
Wang DD
, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing 
of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009;49:1012-1024. 

Incyte Corporation Page 74 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL APPENDIX A. INFORMATION REGARDING EFFECTIVENESS OF 
CONTRACEPTIVE METHODS 
For male participants in the study: 
Male participants should use a condom during treatment and through [ADDRESS_737931] had a vasectomy 
qualify as having met the requirement for a highly effective birth control method. 
For female participants in the study: 
The following methods that can achieve a failure rate of less than 1% per year when used 
consistently and correctly are considered as highly effective birth control methods.  
Such methods include: 
 Combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation1 
 oral 
 intravaginal 
 transdermal 
 Progestogen-only hormonal contraception associated with inhibition of ovulation1 
 oral 
 injectable 
 implantable2 
 Intrauterine device (IUD)2 
 Intrauterine hormone-releasing system (IUS)2 
 Bilateral tubal occlusion2 
 Vasectomised partner2,3 
 Sexual abstinence4 
Acceptable birth control methods that result in a failure rate of more than 1% per year include: 
 progestogen-only oral hormonal contraception, where inhibition of ovulation is not 
the primary mode of action 
 male or female condom with or without spermicide5 
 cap, diaphragm or sponge with spermicide5 
 tubal ligation 
[ADDRESS_737932] low user dependency. 
3  Vasectomised partner is a highly effective method of avoiding pregnancy provided that partner is the sole sexual partner of the 
woman of childbearing potential trial participant and that the vasectomised partner has received medical assessment of the 
surgical success. 
4  In the context of this guidance, sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug.  The reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. 
5 A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods) are also 
considered acceptable, but not highly effective, birth control methods. 
Source:  CTFG 2014. 
Incyte Corporation Page [ADDRESS_737933] a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.  
PD At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD 
recorded since the treatment started, and the sum must also demonstrate an absolute increase of at least 
[ADDRESS_737934] sum LD since the treatment started.  
CR = complete response; LD = longest diameter; PD = progressive disease; PR = partial response; SD = stable disease. 
Evaluation of Nontarget Lesions 
CR Disappearance of all nontarget lesions and normalization of tumor marker level.  
Incomplete non -CR/ 
non-PD/SD  Persistence of 1 or more nontarget lesion(s) and/or maintenance of tumor marker level 
above the normal limits.  
PD Appe arance of 1 or more new lesions and/or unequivocal progression of existing nontarget 
lesions.a 
CR = complete response; PD = progressive disease; SD = stable disease. 
a Although a clear progression of "nontarget" lesions only is exceptional, in such circumstances, the opi[INVESTIGATOR_89164], and the progression status should be confirmed later on by [CONTACT_463] (or study chair). 
Evaluation of Best Overall Response 
 The best overall response is the best response recorded from the start of the treatment 
until disease progression/recurrence (taking as reference for PD the smallest 
measurements recorded since the treatment started).  In general, the participant's best 
response assignment will depend on the achievement of both measurement and 
confirmation criteria. 
 Note:  In nonrandomized studies where response is the primary endpoint, 
confirmation of PR or CR is needed to deem either one the ‘best overall response’. 
Target Lesions  Nontarget Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Incomplete response/SD  No PR 
PR Non-PD or NE  No PR 
SD Non-PD or NE  No SD 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
CR = complete response; PD = progressive disease; PR = partial response; NE = not evaluable; SD = stable disease.  
Incyte Corporation Page 76 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL  Participants with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be 
c
lassified as having “symptomatic deterioration.”  Every effort should be made to 
document the objective progression even after discontinuation of treatment. 
 In some circumstances, it may be difficult to distinguish residual disease from normal 
tissue.  When the evaluation of CR depends on this determination, it is recommended 
that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) to confirm the CR 
status. 
Source:  Eisenhauer et al 2009 . 
Incyte Corporation Page 77 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL APPENDIX C. PROTOCOL AMENDMENT SUMMARY OF CHANGES 
Document  Date  
Amendment (Version) 1:  06 AUG  2018  
Amendment (Version) 2:  [ADDRESS_737935] 2018  
Amendment (Version) 2 -NL: 26 NOV 2018  
Amendment (Version) 3 : 21 MAR  2019 
Amendment (Version) 4:  08 JUL  2019  
Amendment 4 (08 JUL 2019) 
Overall Rationale for the Amendment:  Clarification of eligibility criteria. 
  
 
 
 
 
 
 
 
 
 
3. Section 5.1, Inclusion Criteria 
Description of change:   Revised inclusion criterion #4 as follows: 
Participants must have had progression on or after platinum-based therapy unless 
ineligible for or intolerant of platinum. 
a. No more than 2 prior lines of systemic therapy for metastatic disease  are permitted . 
(this includes radiosensitizing chemotherapy). 
b. Participants who are ineligible for platinum must have received at least 1 prior line of 
systemic therapy.   
c. Participants receiving platinum-based radiosensitizing chemotherapy are 
eligible if relapse occurs < 6 months from completion of treatment. 
Rationale for change:   To clarify the relationship of prior anticancer therapy to 
eligibility. 

Incyte Corporation Page 78 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 4. Section 5.2, Exclusion Criteria(Table 7:  Exclusionary Laboratory Values) 
D
escription of change:   Changed hemoglobin units from L to dL in exclusion 
criterion #5, Table 7. 
R
ationale for change:   To provide consistency throughout the document. 
5. Section 5.2, Exclusion Criteria 
Description of change:   Revised exclusion criterion #13 as follows: 
Participants with impaired cardiac function or clinically significant cardiac disease: 
a. [LOCATION_001] Heart Association Class III or IV cardiac disease, including preexisting 
clinically significant ventricular arrhythmia, congestive heart failure, or 
cardiomyopathy. 
b. Unstable angina pectoris . ≤ 6 months before study participation. 
c. Acute myocardial infarction ≤ 6 months before study participation. 
d. Other clinically significant heart disease (ie, ≥ uncontrolled  Grade 3 hypertension )., 
history of labile hypertension, or poor compliance with an antihypertensive regimen) 
must have recovered (to baseline or ≤ Grade 1) from toxicity associated with prior 
treatment. 
Rationale for change:   To further clarify eligibility as it relates to cardiac diagnoses. 
6. Section 6.6.2, Prohibited Medications and Procedures 
D
escription of change:    Added probiotic dietary supplements as a prohibited 
medication.  
Rationale for change:   To clarify that probiotic dietary supplements are prohibited while 
on study. 
7. Incorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment. 
 
Incyte Corporation Page 79 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Amendment 3 (21 MAR 2019) 
O
verall Rationale for the Amendment:  
 to remove requirement for premedication prophylaxis. 
1. I
ncorporate changes from Amendment 2-NL (26 NOV 2018) 
Description of change:   Changes as listed in Amendment 2-NL (26 NOV 2018) . 
R
ationale for change:   To align Protocol Amendment 3 as appropriate for all regions. 
2. Section 1, Protocol Summary (Table 3 :  Schedule of Activities); Section 6.5.1, 
M
anagement of Suspected Infusion Reactions (Table 9:  Guidelines for Management 
of Suspected Infusion Reactions); Section 6.6.1, Permitted Medications and 
Procedures 
Description of change:  R emoved the requirement for premedication prophylaxis before 
the first dose of INCMGA00012.  
Rationale for change:  Updated for consistency with the INCMGA00012 IB. 
3. Section 1, Protocol Summary (Table 3:  Schedule of Activities); Section 6.6, 
Concomitant Medications and Procedures; Section 8.3, Safety Assessments; 
Section 9.4, Reporting of Serious Adverse Events 
D
escription of change:  Clarified that irAEs are collected up to [ADDRESS_737936] dose of 
study drug.  
Rationale for change:  Immune-related adverse events are collected up to [ADDRESS_737937] dose of study drug. 
4. Section 1, Protocol Summary (Table 5 :  Pharmacokinetic  Sample 
Collections [ ]); Section 3, Objectives and 
Endpoints (Table 6);  
; Section 5.1, Inclusion Criteria (Criterion #9 ); 
Section 8.1.1 Informed Consent Process; Section 8.5, Pharmacodynamic 
 
Assessments;  Section 8.7, End of Treatment and/or Early 
Termination; Section 8.8, Follow-Up; Section [IP_ADDRESS], HIV Viral Control; 
 
Descrip
tion of change:   
 
Rationale
 for change:    
5. Section 2.1.1, INCMGA00012  
Description of change:   Updated INCMGA00012 safety data. 
Rationale for change:   To provide updated data and align with the current IB. 
6. Incorporation of administrative changes.   Other minor, administrative changes 
including updates to the Schedule of Activities (Table 3) have been incorporated 
throughout the Protocol and are noted in the redline version of the amendment. 

Incyte Corporation Page 80 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Amendment 2-NL (26 NOV 2018) 
O
verall Rationale for the Amendment: 
The purpose of this amendment is to address comments regarding the design of the study. 
1. Cover Page 
Description of change:  Added the following statement :  "The research in the 
N
etherlands is carried out in accordance with the Declaration of Helsinki (Brazil, 2013) 
and the WMO (Medical Research Involving Human Subjects Act)." 
Rationale for change:   To clarify. 
2. Section 8.5.1, Description of Analyses 
Description of change:   Added the following text:  "Biological samples will be stored 
for up to [ADDRESS_737938] clinical study report publication.  The research performed 
on those samples will be study-related.  Additional research outside of study-related 
research will not be performed." 
Rationale for change:   To clarify how long the body material is stored after the 
investigation and for which purpose this material is stored. 
3. Section 11.3, Data Privacy and Confidentiality of Study Records 
Description of change:   Added the following text:  "In the Netherlands, it is mandatory 
t
o keep the data for 15 years after the end of the research." 
Rationale for change:   To clarify how long the data will be stored at the research 
location in the Netherlands. 
4. I
ncorporation of administrative changes.   Other minor, administrative changes have 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment.  
Incyte Corporation Page 81 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Amendment 2 ([ADDRESS_737939] 2018) 
O
verall Rationale for the Amendment: 
The purpose of this amendment is to address comments regarding the design of the study. 
1. Section 1, Protocol Summary; Section 4.3, Study Termination; Section 4.3.1, Data 
Monitoring Committee; Section 10.5 Futility Analysis 
Description of change:   Added a DMC. 
R
ationale for change:   To clarify that an independent DMC will be formed. 
2. Section 5.1, Inclusion Criteria 
Description of change:   Inclusion criterion #4 was revised as follows:  
Participants must have received no more than [ADDRESS_737940] received (or been intolerant to or ineligible for) at least 1 prior line of 
platinum based chemotherapy and received no more than 2 prior systemic treatments. 
Rationale for change:   To clarify that participants will be included if they progressed 
a
fter standard-of-care platinum-based chemotherapy. 
3. S
ection 5.2, Exclusion Criteria 
Description of change:   Exclusion criterion #2 was revised as follows: 
R
adiotherapy within [ADDRESS_737941] dose of study treatment with the following caveats:  
a. 28 days for pelvic radiotherapy. 
b. 6 months for thoracic region radiotherapy that is > 30 Gy in 2 Gy fractions. 
Rationale for change:   To clarify that the limit is a total dose equivalent to 30 Gy in 
2 Gy fractions. 
4. Section 5.2, Exclusion Criteria 
Description of change:   Exclusion Criterion #12 was revised as follows: 
Known hypersensitivity to another monoclonal antibody that cannot be controlled with 
standard measures (eg, antihistamines and corticosteroids) or known allergy or 
hypersensitivity to any component of INCMGA00012 or formulation components. 
Rationale for change:   To clarify that known hypersensitivity to any excipi[INVESTIGATOR_561519] 
i
n the INCMGA00012 drug formulation is exclusionary. 
Incyte Corporation Page 82 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 5. Section [IP_ADDRESS], Immune-Mediated Myocarditis (Table 17:  Recommended Approach 
for Handling Myocarditis) 
Description of change:   Added Section [IP_ADDRESS], Immune-Mediated Myocarditis. 
R
ationale for change:   To add guidance regarding management of immune-mediated 
myocarditis. 
6. Section 10.5, Futility Analysis 
Description of change:   Added additional details to clarity the stoppi[INVESTIGATOR_561520]. 
Rationale for change:   To clarify criteria for stoppi[INVESTIGATOR_48621]. 
Incyte Corporation Page 83 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL Amendment 1 (06 AUG  2018) 
Overall Rationale for the Amendment: 
The primary purpose of this amendment is to address comments regarding the design of the 
study. 
1. Section 1, Protocol Summary (Table 3, Schedule of Activities); Section 4.1, Overall 
Design; Section 8.3.1, Adverse Events; Section 8.3.6, Laboratory Assessments; 
Section 8.8.1, Safety Follow-Up; Section 9.4, Reporting of Serious Adverse Events 
Description of change:   Updated text to reflect that participants will be evaluated for 
AEs for [ADDRESS_737942]. 
Rationale for change:   Participants will be followed for AEs for [ADDRESS_737943] 
dose of study drug, regardless of whether a new anticancer therapy is started. 
2. Section 5.1, Inclusion Criteria (Inclusion Criterion #4) 
Description of change:   Updated Inclusion Criterion #4: 
4.  No more than [ADDRESS_737944] included 
platinum based chemotherapy unless the participant is intolerant of platinum therapy, is 
ineligible for platinum, or has refused platinum based chemotherapy (with medical 
monitor approval). 
4.  Must have received (or been intolerant to or ineligible for) at least 1 prior line of 
platinum-based chemotherapy and received no more than 2 prior systemic treatments. 
Rationale for change:   To clarify the eligibility criteria to explicitly state that 
participants must have received (or been intolerant to or ineligible for) at least 1 prior line 
of platinum-based systemic therapy to be eligible. 
3. Section 1, Protocol Summary (Table 3, Schedule of Activities); Section 8.3.6, 
Laboratory Assessments; Section 8.3.6, Laboratory Assessments (Table 18, 
Required Laboratory Analytes) 
Description of change:   Added:   
 
   
 
 
Rationale for change:    
 
 

Incyte Corporation Page 84 of 84 
P
rotocol INCM GA 0012 -202 Am 4 Version 4 08 JUL 2019  
CONFIDENTIAL 4. Section 1, Protocol Summary (Table 4, Pharmacokinetic  Sample 
Collection); Section 8.5.1, Description of Analysis 
Description of change:    
 
Rationale for change:    
 
5. Section 1, Protocol Summary (Table 4, Pharmacokinetic  Sample 
Collections) 
Description of change:   
 
Rationale for change:    
 
6. Section 6.6.1, Permitted Medications and Procedures 
Description of change:   Added:  Highly active antiretroviral therapy (HAART) should 
be continued for participants who are known to be HIV positive. 
Rationale for change:   To clarify that HAART is a permitted medication in this study. 
  
 
 
 
 
8. Section 10.2, Population for Analysis; Section [IP_ADDRESS], Handling of Missing Data in 
Primary Analysis 
Description of change:   Edited Full Analysis Set (FAS):  The FAS includes all 
participants enrolled in the study have measurable disease per RECIST v1.1who received 
at least 1 dose of study drug.  The FAS will be used for the summary of demographics, 
baseline characteristics, and participant disposition as well as efficacy analysis. 
Rationale for change:   Measurable disease by [CONTACT_393] v1.1 is an eligibility criterion. 
9. Section 3, Objectives and Endpoints (Table 5, Objectives and Endpoints); 
Section [IP_ADDRESS], Disease Control Rate 
D
escription of change:   Edited Disease Control Rate (DCR):  DCR, defined as the 
number of participants maintaining either an ORR or stable disease lasting at least 6 
months. 
Rationale for change:   In SCAC, DCR does not require maintaining SD for [ADDRESS_737945] 
been incorporated throughout the Protocol and are noted in the redline version of the 
amendment. 
